1,014 results on '"Sampaio, C."'
Search Results
102. Pilot Study of the Combination of Melphalan, Carboplatin and Etoposide as a Conditioning Regimen for Relapsed Lymphoma Patients
- Author
-
del Giglio, A., Costa, L. J.M., Pinczowski, H., Varella, P. C.S., Luzzi, J. R., Neves, P., Mota, A., Boente, P., and Sampaio, C.
- Published
- 1999
- Full Text
- View/download PDF
103. Health, environment and reemerging disease: dengue in the Amazon
- Author
-
Sampaio, C??nthia Maria Teixeira, Albuquerque, Adorea Rebello da Cunha, Ador??a Rebello da Cunha Albuquerque, Ador??a, Jos?? Camilo de Souza Ramos, Jos??, and Natacha Cintia Regina Aleixo, Natacha
- Subjects
Dengue na Amaz??nia ,GEOGRAFIA [CI??NCIAS HUMANAS] - Abstract
Submitted by C??nthia Sampaio (cinthia-sampaio2011@hotmail.com) on 2018-12-21T07:34:55Z No. of bitstreams: 2 Disserta????o C??nthia (2018).pdf: 7023636 bytes, checksum: 8355d1f9425d46f1e1286e6313aac51d (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Approved for entry into archive by Geografia PPG (ppgeog@ufam.edu.br) on 2019-01-14T17:39:13Z (GMT) No. of bitstreams: 2 Disserta????o C??nthia (2018).pdf: 7023636 bytes, checksum: 8355d1f9425d46f1e1286e6313aac51d (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Approved for entry into archive by Geografia PPG (ppgeog@ufam.edu.br) on 2019-01-14T17:39:52Z (GMT) No. of bitstreams: 2 Disserta????o C??nthia (2018).pdf: 7023636 bytes, checksum: 8355d1f9425d46f1e1286e6313aac51d (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Made available in DSpace on 2019-01-14T17:39:52Z (GMT). No. of bitstreams: 2 Disserta????o C??nthia (2018).pdf: 7023636 bytes, checksum: 8355d1f9425d46f1e1286e6313aac51d (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2018-09-19 92 984517107 The Amazonas state faces serious public health problems related to the prevalence of dengue cases. Included in the group of diseases reemerging dengue, data that been controlled, resurfaces intensively at the present time. The analyzes and interpretations, obtained from the results of this study indicated that the municipalities with the highest prevalence of dengue, in the period corresponding to the years of 2007 to 2012, were S??o Gabriel da Cachoeira (700.260), Manaus (657.15), 539.18 (44.15), Tef?? (533.43), Novo Aripuan?? (465.81), Coari (373.76). Thus, understanding the context of increasing cases of dengue related to both environmental factors, climatic and seasonality as well as those associated those with issues of production urban space is need to undertake actions to confront this reality. The data revealed that the months of higher hospitalization coincided with beginning of the rainy period in the municipalities however the reduced network of basic sanitation if presented as a conditioning factor to be considered, since in this period the accumulated water, causes flood. On the other the relationship between outbreaks off fires and deforestation, showed no significant correlations, indicated by low records of dengue in the platforms of health. The methodology of this study developed using the database of the Ministry of Health (DATASUS) and the the foundation of health surveillance of the Amazon. The calculation of prevalence included the number of cases of dengue (probable) divided by the population of given geographical area expressed per 100 thousands inhabitant. One of the factors that intensified the dengue in the state of Amazonas was the demographic partner when associated to the movement of people as a result of the opening of work fronts, territorial occupation and income. Coari was a municipality that received a large flow of people for the execution of the Works of the Pipeline Urucu/Coari/Manaus. The cities of the South of Amazonas such as Humait?? and Novo Aripuan??, approaching the arch of deforestation, presented growth of the disease. S??o Gabriel da Cachoeira located in the North and Tabatinga in the triple border with Colombia and Peru, Guajar?? border with Peru and border with the state of Acre also showed high rates. O estado do Amazonas enfrenta s??rios problemas de sa??de p??blica relacionados ?? preval??ncia de dengue. Inclu??da no grupo das doen??as reemergentes, a dengue, de dados que tinha sido controlada, ressurge de forma intensa na atualidade. As an??lises e interpreta????es, obtidas a partir dos resultados deste trabalho, indicaram que os munic??pios de maior preval??ncia de dengue, no per??odo correspondente aos anos de 2007 a 2012, foram S??o Gabriel da Cachoeira (700,26), Manaus (657,15), Humait?? (539,18), Tef?? (533,43), Novo Aripuan?? (465,81), Coari (373,76). Sendo assim, compreender o contexto do aumento dos casos de dengue relacionados tanto fatores ambientais, clim??tico e sazonalidade, quanto aqueles associados ??s quest??es de produ????o do espa??o urbano constitui-se necessidade para empreender a????es de enfrentamento a essa realidade. Os dados revelaram que os meses de maior interna????o coincidem com o in??cio do per??odo chuvoso nos munic??pios, todavia, a reduzida rede de saneamento b??sico, se apresentou como uma condicionante a ser considerada, uma vez que, neste per??odo, a ??gua al??m de ficar acumulada, causa inunda????es. Por outro lado, a rela????o entre focos de queimadas e desmatamentos, n??o apresentou correla????es significantes, indicados pelos baixos registros de dengue nas plataformas de sa??de. A metodologia deste estudo utiliza o banco de dados do Minist??rio da Sa??de (DATASUS) e da Funda????o de Vigil??ncia em Sa??de do Amazonas. O c??lculo da preval??ncia incluiu o n??mero de casos novos (prov??veis) de dengue dividido pela popula????o de determinada ??rea geogr??fica, expresso por 100 mil habitantes. Um dos fatores que intensificou a dengue no estado do Amazonas foi o sociodemogr??fico quando associado ?? circula????o das pessoas em decorr??ncia da abertura de frentes de trabalho, ocupa????o territorial e renda. Coari foi um munic??pio que recebeu grande fluxo de pessoas para a execu????o das obras do Gasoduto Urucu/Coari/Manaus. Os munic??pios do sul do Amazonas como Humait?? e Novo Aripuan??, que se aproximam do Arco do Desmatamento, apresentaram crescimento da doen??a. S??o Gabriel da Cachoeira localizado na Faixa de Fronteira Norte e Tabatinga na Tr??plice Fronteira com a Col??mbia e Peru; Guajar?? fronteira com Peru e limite com o estado do Acre tamb??m apresentaram ??ndices elevados. A problem??tica da dengue nos munic??pios do Amazonas, a pesquisa mostra os locais de risco da doen??a para auxiliarem as pol??ticas p??blicas com o objetivo de amenizar o problema.
- Published
- 2018
104. Posters display III clinical outcome and PET
- Author
-
Baliño, N., Masoli, O., Traverso, S., Grynberg, L., Rappallo, C., Redruello, M., Rosa, D., Cragnolino, D., Meretta, A., Vidal, L., Graf, S., Khorsand, A., Gyongyosi, M., Karanikas, G., Eidherr, H., Kletter, K., Porenta, G., Glogar, D., Sochor, H., Beheshti, M., Poetzi, C., Wadsak, W., Maurer, G., Wolfram, J., Winter, O., Velghe, A., Veire, N., Bondt, P., Buyzere, M., Wiele, C., Backer, G., Gillebert, T., Dierckx, R., Sutter, J., Bernard, D., Langlois, M., Duarte, P., Mastrocolla, L., Sampaio, C., Rossi, J., Smanio, P., Lima, E., Oliveira, C., Pereira, J., Beraldo, P., Rodrigues, F., Thom, A., Yoshinaga, K., Ukkonen, H., Burwash, I., DeKemp, R., Dafoe, W., Davies, R., Haddad, H., Ruddy, T., DaSilva, J., Beanlands, R., Chow, B., Williams, K., Garrard, L., Szeto, A., Aung, M., Sondergaard, H., Bottcher, M., Madsen, M., Schmitz, O., Nielsen, T., Botker, H., Høilund-Carlsen, P., Johansen, A., Christensen, H., Vach, W., Møldrup, M., Haghfelt, T., Kristensen, J., Maeng, M., Mortensen, U., Berg, J., Rehling, M., Elsaban, K., El-Kady, T., El-Gabaly, M., Yehia, A., El-Sayed, M., Naum, A., Laaksonen, M., Tuunanen, H., Oikonen, V., Kemppainen, J., Järvisalo, M., Nuutila, P., Knuuti, J., Vanzetto, G., Jacon, P., Fagret, D., Machecourt, J., Lindner, O., Vogt, J., Kammeier, A., Fricke, E., Wielepp, P., Baller, D., Lamp, B., Holzinger, J., Horstkotte, D., Burchert, W., Nekolla, S., Souvatzoglou, M., Hausleiter, J., Henke, N., Kruschke, K., Bengel, F., Schwaiger, M., Sundaram, P., Padma, S., Haridas, K., Kumar, S., Zachariah, M., Livschitz, S., Zornitzki, T., Vered, S., Oettinger, M., Levy, R., Caspi, A., Faraggi, D., Knobler, H., Mats, I., Solodky, A., Ben-Gal, T., Battler, A., Zafrir, N., Varani, E., Balducelli, M., Severi, S., Patroncini, A., Vecchi, G., Gatti, C., Corbelli, C., Casanova, R., Maresta, A., Cittanti, C., Valgimigli, M., Giganti, M., Malagutti, P., Percoco, G., Bagatin, E., Panareo, S., Avigni, N., Ferrari, R., Feggi, L., Filardi, P., Cuocolo, A., Storto, G., Brevetti, G., Dellegrottaglie, S., Corrado, L., Cafiero, M., Polimeno, M., Zarrilli, A., Chiariello, M., Marcassa, C., Campini, R., Calza, P., Giannuzzi, P., Galassi, A., Grasso, C., Azzarelli, S., Leotta, E., Moshiri, S., Tamburino, C., Acampa, W., Ferro, A., Petretta, M., Salvatore, M., Pieri, P., Berta, R., Moscatelli, G., Buccoliero, F., Inglese, E., Medolago, G., Imperiale, A., Rimini, M., Bertagna, F., Sullo, P., Lupo, M., Cappagli, M., Fukuda, H., Kunimasa, T., Furuhashi, T., Moroi, M., Yasuhi, W., Akihiro, S., Akio, Y., Ryou, K., Kimio, T., Yasunori, W., Yasuhiko, T., Nariaki, E., Watabe, H., Teramoto, N., Ohta, Y., Kou, Y., Hayashi, T., Iida, H., Bom, H., Song, H., Min, J., Heo, Y., Seo, J., Lee, J., Bae, J., Jeong, S., Ahn, B., Chae, S., Lee, K., Popiel, M., Grajek, S., Czepczynski, R., Breborowicz, P., Lesiak, M., Czyz, A., Sawinski, K., Komarnicki, M., Cieslinski, A., Sowinski, J., Ferreira, A., Ventosa, A., Gil, V., Calqueiro, J., Lima, S., Aguiar, C., Couto, R., Raposo, L., Seabra-Gomes, R., Vasconcelos, M., Martins, E., Faria, T., Oliveira, A., Garcia, M., Rocha-Gonçalves, F., Lourenço, C., Roque, C., Ferrer-Antunes, A., Ferreira, M., Providência, L., Lima, J., Medrea, C., Bogdan, R., Lazar, A., Mot, S., Capilneanu, R., Kozulin, V., Berkovich, O., Ivashchenko, T., Larionova, V., Esipovich, I., Gordeev, M., Panov, A., Shlyakhto, E., Burova, N., Baranov, D., Timoshin, V., Chuprova, S., Shkolnikova, M., Zaklyazminskaya, E., Poliakov, A., Sazonova, S., Romero-Farina, G., Arenillas, J., Candell-Riera, J., Aguadè-Bruix, S., Leon, G., Molina, C., Chacon, P., Montaner, J., Rovira, A., Alvarez-Sabin, J., Namdar, M., Siegrist, P., Grathwohl, R., Delaloye, R., Koepfli, P., Wyss, C., Kaufmann, P., Bartenstein, N., Hellermann, J., Pollack, C., Schurr, U., Zellweger, M., Burger, P., Mueller-Brand, J., Pfisterer, M., Gordon, L., Epps, A., Chiarameda, S., Navare, S., Ahlberg, A., Cyr, G., Katten, D., Ausef, A., Heller, G., Darrow, B., Thomas, G., Ip, T., Thompson, R., Kramer, D., Rice, D., Thomas, J., Miyamoto, M., Druz, R., Nichols, K., Akinboboye, O., Reichek, N., Podrasky, E., Tuttle, R., Shaw, L., Hanson, M., Borges-Neto, S., Lundbye, J., Werden, S., Kazi, F., Whalen, A., Noble, G., O'Sullivan, D., Boden, W., Danias, P., Papaioannou, G., Leka, I., Beretta, M., Viňas, S., Gonzalez, A., Vidal, I., and Rener, A.
- Published
- 2018
105. Quality of Life in Huntington's Disease: Critique and Recommendations for Measures Assessing Patient Health-Related Quality of Life and Caregiver Quality of Life
- Author
-
Mestre, T. A., Carlozzi, N. E., Ho, A. K., Burgunder, Jean-Marc, Walker, F., Davis, A. M., Busse, M., Quinn, L., Rodrigues, F. B., Sampaio, C., Goetz, C. G., Cubo, E., Martinez-Martin, P., and Stebbins, G. T.
- Subjects
610 Medicine & health - Abstract
The compromise of quality of life in Huntington's disease is a major issue, both for individuals with the disease as well as for their caregivers. The International Parkinson and Movement Disorder Society commissioned a review of the use and clinimetric validation status of measures used in Huntington's disease to assess aspects related with quality of life and to make recommendations on their use following standardized criteria. We included both patient-centered measures (patient health-related quality-of-life measures) and caregiver-centered measures (caregiver quality-of-life measures). After conducting a systematic literature search, we included 12 measures of patient health-related quality of life and 2 measures of caregiver quality of life. Regarding patient-centered measures, the Medical Outcomes Study 36-Item Short-Form Health Survey is "recommended" as a generic assessment of health-related quality of life in patients with Huntington's disease. The 12-Item Short Form Health Survey, the Sickness Impact Profile, the 12-item World Health Organization Disability Assessment Schedule, and the Huntington's Disease Health-Related Quality of Life questionnaire are "suggested." No caregiver-centered quality-of-life measure obtained a "recommended" status. The Alzheimer's Carer's Quality of Life Inventory and the Huntington's Disease Quality of Life Battery for Carers are "suggested." Recognizing that the assessment of patient health-related quality of life can be challenging in Huntington's disease, as patients may lack insight and there is insufficient clinimetric testing of these scales, the committee concluded that further validation of currently available health-related quality-of-life measures should be undertaken, namely, those Huntington's disease-specific health-related quality-of-life measures that have recently been reported and used. (c) 2018 International Parkinson and Movement Disorder Society.
- Published
- 2018
- Full Text
- View/download PDF
106. Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)§
- Author
-
Winkelmann, J., Allen, R.P., Hoegl, B., Inoue, Y., Oertel, W., Salminen, A.V., Winkelman, J.W., Trenkwalder, C., and Sampaio, C.
- Subjects
Restless Legs Syndrome (rls) ,Evidence-based Medicine ,Guidelines ,Mds Recommendations ,Therapy ,Treatment ,Augmentation - Abstract
The objective of the current review was to update the previous evidence-based medicine review of treatments for restless legs syndrome published in 2008. All randomized, controlled trials (level I) with a high quality score published between January 2007 and January 2017 were reviewed. Forty new studies qualified for efficacy review. Pregabalin, gabapentin enacarbil, and oxycodone/naloxone, which did not appear in the previous review, have accrued data to be considered efficacious. Likewise, new data enable the modification of the level of efficacy for rotigotine from likely efficacious to efficacious. Intravenous ferric carboxymaltose and pneumatic compression devices are considered likely efficacious in idiopathic restless legs syndrome. Bupropion and clonidine were reviewed, but the lack of data determined a rating of insufficient evidence for efficacy. The following interventions continue to be considered efficacious as in 2008: levodopa, ropinirole, pramipexole, cabergoline, pergolide, and gabapentin. Bromocriptine, oxycodone, carbamazepine, and valproic acid are considered likely efficacious. Oral iron is nonefficacious in iron-sufficient subjects, but its benefit for patients with low peripheral iron status has not been adequately evaluated. Restless legs syndrome augmentation has been identified as a significant long-term treatment complication for pramipexole more than pregabalin and possibly for all dopaminergic agents more than alpha 2 delta ligands. Therefore, special monitoring for augmentation is required for all dopaminergic medications as well as tramadol. Other drugs also require special safety monitoring: cabergoline, pergolide, oxycodone, methadone, tramadol, carbamazepine, and valproic acid. Finally, we also highlighted gaps and needs for future clinical research and studies of restless legs syndrome.
- Published
- 2018
107. Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations
- Author
-
Mestre, T. A., Busse, M., Davis, A. M., Quinn, L., Rodrigues, F. B., Burgunder, Jean-Marc, Carlozzi, N. E., Walker, F., Ho, A. K., Sampaio, C., Goetz, C. G., Cubo, E., Martinez-Martin, P., and Stebbins, G. T.
- Subjects
610 Medicine & health - Abstract
Limitation of functional ability is a major feature of Huntington's disease (HD). The International Parkinson and Movement Disorder Society (MDS) commissioned the appraisal of the use and clinimetric properties of clinical measures of functional ability that have been applied in HD studies and trials to date, to make recommendations regarding their use based on standardized criteria. After a systematic literature search, we included a total of 29 clinical measures grouped into two categories: (1) performance-based measures (e.g., balance, walking, and reaching/grasping), and (2) rating scales. Three performance-based measures are rated as "recommended": the Tinetti Mobility Test for screening of fall risk and for severity assessment of mobility in patients with manifest HD (up to stage III); the Berg Balance Scale for severity of balance impairment; and the Six-Minute Walk Test for assessment of walking endurance (severity) in HD subjects with preserved ambulation. No rating scale targeting functional ability reached a "recommended" status either for screening or severity measurement. The main challenges identified in this review include applying widely accepted conceptual frameworks to the identified measures, the lack of validation of clinical measures to detect change over time, and absence of validated measures for upper limb function. Furthermore, measures of capacity or ability to perform activities of daily living had ceiling effects in people with early and pre-manifest HD. We recommend that the MDS prioritize the development of new scales that capture small, but meaningful changes in function over time for outcome assessment in clinical trials, particularly in earlier stages of HD.
- Published
- 2018
- Full Text
- View/download PDF
108. Integrating road traffic externalities through a sustainability indicator
- Author
-
Fernandes, P., primary, Vilaça, M., additional, Macedo, E., additional, Sampaio, C., additional, Bahmankhah, B., additional, Bandeira, J.M., additional, Guarnaccia, C., additional, Rafael, S., additional, Fernandes, A.P., additional, Relvas, H., additional, Borrego, C., additional, and Coelho, M.C., additional
- Published
- 2019
- Full Text
- View/download PDF
109. ESRA19-0214 Regional anesthesia as a safe approach in the malignant-hyperthermia susceptible patient scheduled for cesarean delivery
- Author
-
Gonçalves, D, primary, Sampaio, C, additional, Godinho, H, additional, Roriz, D, additional, Brandão, J, additional, Sá, M, additional, and Abrunhosa, R, additional
- Published
- 2019
- Full Text
- View/download PDF
110. TERT promoter and FGFR3 mutations – a highly sensitive and non-invasive tool for bladder cancer recurrence detection
- Author
-
Leão, R., primary, Batista, R., additional, Sampaio, C., additional, Peralta, P., additional, Conceição, P., additional, Sismeiro, A., additional, Torres, N., additional, Almeida, F., additional, Prazeres, H., additional, Vinagre, J., additional, and Soares, P., additional
- Published
- 2019
- Full Text
- View/download PDF
111. Abstract GS2-04: Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer
- Author
-
Martín, M, primary, Barrios, CH, additional, Torrecillas, L, additional, Ruiz-Borrego, M, additional, Bines, J, additional, Segalla, J, additional, Ruiz, A, additional, García-Sáenz, JA, additional, Torres, R, additional, de la Haba, J, additional, García, E, additional, Gómez, HL, additional, Llombart, A, additional, Rodríguez de la Borbolla, M, additional, Baena, JM, additional, Barnadas, A, additional, Calvo, L, additional, Pérez-Michel, L, additional, Ramos, M, additional, Castellanos, J, additional, Rodríguez-Lescure, A, additional, Cárdenas, J, additional, Vinholes, J, additional, Martínez de Dueñas, E, additional, Godes, MJ, additional, Seguí, MA, additional, Antón, A, additional, López-Álvarez, P, additional, Moncayo, J, additional, Amorim, G, additional, Villar, E, additional, Reyes, S, additional, Sampaio, C, additional, Cardemil, B, additional, Escudero, MJ, additional, Bezares, S, additional, Carrasco, E, additional, and Lluch, A, additional
- Published
- 2019
- Full Text
- View/download PDF
112. 445 Protein supplementation in late gestation affects maternal skeletal muscle gene expression and plasma circulating amino acids.
- Author
-
Gionbelli, M, primary, Lopes, R, additional, Trece, A, additional, Teixeira, P, additional, Duarte, M, additional, and Sampaio, C, additional
- Published
- 2018
- Full Text
- View/download PDF
113. 362. Performance evaluation of an orthopaedic dedicated, novel cone-beam CT scanner
- Author
-
Zagni, F., primary, Durante, S., additional, Pierotti, L., additional, Sampaio, C., additional, Vichi, S., additional, and Marengo, M., additional
- Published
- 2018
- Full Text
- View/download PDF
114. Caiman Kininogen-Like Cysteine Proteinase Inhibitor
- Author
-
Araujo, M. S., primary, Andreotti, R., additional, Chudzinski, A. M., additional, Sampaio, C. A. M., additional, and Sampaio, M. U., additional
- Published
- 1992
- Full Text
- View/download PDF
115. Further Characterization of Endopeptidase H2 a Serine Proteinase from Human Urine
- Author
-
Casarini, D. E., primary, Fellows, C. E., additional, Stella, R. C. R., additional, and Sampaio, C. A. M., additional
- Published
- 1992
- Full Text
- View/download PDF
116. Biomarkers in clinical trials of Alzheimer Disease (AD): What is expected from regulatory agencies?
- Author
-
Sampaio, C.
- Published
- 2009
- Full Text
- View/download PDF
117. Design Optimization for Clinical Trials in Early-Stage Manifest Huntington's Disease
- Author
-
Frost, C., Mulick, A., Scahill, R.I., Owen, G., Aylward, E., Leavitt, B.R., Durr, A., Roos, R.A.C., Borowsky, B., Stout, J.C., Reilmann, R., Langbehn, D.R., Tabrizi, S.J., Sampaio, C., and TRACK-HD Investigators
- Subjects
trial design Huntington's - Abstract
OBJECTIVES: The purpose of this study was to inform the design of randomized clinical trials in early-stage manifest Huntington's disease through analysis of longitudinal data from TRACK-Huntington's Disease (TRACK-HD), a multicenter observational study. METHODS: We compute sample sizes required for trials with candidate clinical, functional, and imaging outcomes, whose aims are to reduce rates of change. The calculations use a 2-stage approach: first using linear mixed models to estimate mean rates of change and components of variability from TRACK-HD data and second using these to predict sample sizes for a range of trial designs. RESULTS: For each outcome, the primary drivers of the required sample size were the anticipated treatment effect and the duration of treatment. Extending durations from 1 to 2 years yielded large sample size reductions. Including interim visits and incorporating stratified randomization on predictors of outcome together with covariate adjustment gave more modest, but nontrivial, benefits. Caudate atrophy, expressed as a percentage of its baseline, was the outcome that gave smallest required sample sizes. DISCUSSION: Here we consider potential required sample sizes for clinical trials estimated from naturalistic observation of longitudinal change. Choice among outcome measures for a trial must additionally consider their relevance to patients and the expected effect of the treatment under study. For all outcomes considered, our results provide compelling arguments for 2-year trials, and we also demonstrate the benefits of incorporating stratified randomization coupled with covariate adjustment, particularly for trials with caudate atrophy as the primary outcome. The benefits of enrichment are more debatable, with statistical benefits offset by potential recruitment difficulties and reduced generalizability. © 2017 International Parkinson and Movement Disorder Society.
- Published
- 2017
118. Motor, cognitive, and functional declines contribute to a single progressive factor in early HD
- Author
-
Schobel, S.A., Palermo, G., Auinger, P., Long, J.D., Ma, S.Y., Khwaja, O.S., Trundell, D., Cudkowicz, M., Hersch, S., Sampaio, C., Dorsey, E.R., Leavitt, B.R., Kieburtz, K.D., Sevigny, J.J., Langbehn, D.R., Tabrizi, S.J., TRACK-HD Huntington Study Grp, COHORT Huntington Study Grp, CARE-HD Huntington Study Grp, and 2CARE Huntington Study Grp
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,Ubiquinone ,Apathy ,Emotions ,Disease ,Neuropsychological Tests ,Signal-To-Noise Ratio ,Placebo group ,Article ,03 medical and health sciences ,0302 clinical medicine ,Physical medicine and rehabilitation ,Atrophy ,Rating scale ,medicine ,Humans ,Cognitive Dysfunction ,Longitudinal Studies ,Prospective Studies ,Randomized Controlled Trials as Topic ,business.industry ,Reproducibility of Results ,Cognition ,Vitamins ,Middle Aged ,medicine.disease ,Clinical trial ,030104 developmental biology ,Huntington Disease ,Social Perception ,Motor Skills ,Stroop Test ,Disease Progression ,Observational study ,Female ,Neurology (clinical) ,business ,Facial Recognition ,030217 neurology & neurosurgery ,Cohort study - Abstract
Objective:To identify an improved measure of clinical progression in early Huntington disease (HD) using data from prospective observational cohort studies and placebo group data from randomized double-blind clinical trials.Methods:We studied Unified Huntington Disease Rating Scale (UHDRS) and non-UHDRS clinical measures and brain measures of progressive atrophy in 1,668 individuals with early HD followed up prospectively for up to 30 to 36 months of longitudinal clinical follow-up.Results:The results demonstrated that a composite measure of motor, cognitive, and global functional decline best characterized clinical progression and was most strongly associated with brain measures of progressive corticostriatal atrophy.Conclusions:Use of a composite motor, cognitive, and global functional clinical outcome measure in HD provides an improved measure of clinical progression more related to measures of progressive brain atrophy and provides an opportunity for enhanced clinical trial efficiency relative to currently used individual motor, cognitive, and functional outcome measures.
- Published
- 2017
119. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: A randomised, placebo-controlled trial
- Author
-
Poewe, W., Seppi, K., Fitzer Attas, C. J., Wenning, G. K., Gilman, S., Low, P. A., Giladi, N., Barone, P., Sampaio, C., Eyal, E., Rascol, O., Rasagiline for MSA investigators [. . ., CORTELLI, PIETRO, Poewe, W., Seppi, K., Fitzer-Attas, C.J., Wenning, G.K., Gilman, S., Low, P.A., Giladi, N., Barone, P., Sampaio, C., Eyal, E., Rascol, O., Rasagiline-for-MSA investigators [.., Cortelli, P., and ]
- Subjects
Male ,medicine.medical_specialty ,Population ,Neuroprotective Agent ,Placebo-controlled study ,Placebo ,law.invention ,Aged ,Double-Blind Method ,Female ,Humans ,Indans ,Middle Aged ,Multiple System Atrophy ,Neuroprotective Agents ,Parkinsonian Disorders ,Treatment Outcome ,Neurology (clinical) ,Medicine (all) ,chemistry.chemical_compound ,Atrophy ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Clinical endpoint ,education ,Rasagiline ,education.field_of_study ,Intention-to-treat analysis ,business.industry ,Indan ,Parkinsonian Disorder ,medicine.disease ,Surgery ,chemistry ,business ,Human - Abstract
Summary Background Multiple system atrophy is a complex neurodegenerative disorder for which no effective treatment exists. We aimed to assess the effect of rasagiline on symptoms and progression of the parkinsonian variant of multiple system atrophy. Methods We did this randomised, double-blind, placebo-controlled trial between Dec 15, 2009, and Oct 20, 2011, at 40 academic sites specialised in the care of patients with multiple systemic atrophy across 12 countries. Eligible participants aged 30 years or older with possible or probable parkinsonian variant multiple system atrophy were randomly assigned (1:1), via computer-generated block randomisation (block size of four), to receive either rasagiline 1 mg per day or placebo. Randomisation was stratified by study centre. The investigators, study funder, and personnel involved in patient assessment, monitoring, analysis and data management were masked to group assignment. The primary endpoint was change from baseline to study end in total Unified Multiple System Atrophy Rating Scale (UMSARS) score (parts I and II). Analysis was by modified intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00977665. Findings We randomly assigned 174 participants to the rasagiline group (n=84) or the placebo group (n=90); 21 (25%) patients in the rasagiline group and 15 (17%) in the placebo group withdrew from the study early. At week 48, patients in the rasagiline group had progressed by an adjusted mean of 7·2 (SE 1·2) total UMSARS units versus 7·8 (1·1) units in those in the placebo group. This treatment difference of −0·60 (95% CI −3·68 to 2·47; p=0·70) was not significant. 68 (81%) patients in the rasagiline group and 67 (74%) patients in the placebo group reported adverse events, and we recorded serious adverse events in 29 (35%) versus 23 (26%) patients. The most common adverse events in the rasagiline group were dizziness (n=10 [12%]), peripheral oedema (n=9 [11%]), urinary tract infections (n=9 [11%]), and orthostatic hypotension (n=8 [10%]). Interpretation In this population of patients with the parkinsonian variant of multiple system atrophy, treatment with rasagiline 1 mg per day did not show a significant benefit as assessed by UMSARS. The study confirms the sensitivity of clinical outcomes for multiple system atrophy to detect clinically significant decline, even in individuals with early disease. Funding Teva Pharmaceutical Industries and H Lundbeck A/S.
- Published
- 2015
120. Impacts of protein supplementation during late gestation of beef cows on maternal skeletal muscle and liver tissues metabolism.
- Author
-
Lopes, R. C., Sampaio, C. B., Trece, A. S., Teixeira, P. D., Gionbelli, T. R. S., Santos, L. R., Costa, T. C., Duarte, M. S., and Gionbelli, M. P.
- Abstract
Since nutritional requirements are increased at the end of gestation to meet the demands of the pregnant uterus, pregnant beef cows are susceptible to mobilization of body reserves (mainly fat and amino acids (AAs)) and to alter the metabolism of nutrients in the liver and muscle to support such demands. The objective of this study was to evaluate the effect of CP supplementation on maternal nutrient metabolism in the late gestation of beef cows grazing a low-quality pasture. Forty-three pregnant Nellore cows gestating male fetuses (average age = 6 years; average weight = 544 kg) at 193 ± 30 (mean ± SD) days (d) of gestation were divided into eight groups (experimental units, with four to five cows each). Treatments were (1) control (CON, n = 4): pasture-based (PB) diet without CP supplementation and (2) supplemented (SUP, n = 4): PB diet daily supplemented with 2 g/kg of BW of a 43.5% CP supplement. Liver and skeletal muscle biopsies were performed at 265 days of gestation and samples were collected for mRNA expression. On day 280 of gestation, blood samples were collected to assess plasma levels of AA. The CON-fed cows tended to have greater (P = 0.057) total circulating AA than SUP-fed cows. The circulating glycogenic AA was greater (P = 0.035) in CON than in SUP cows. CON cows was greater for histidine (P = 0.015), methionine (P = 0.007) and alanine (P = 0.036) than SUP cows. The CON- and SUP-fed showed no differences for gluconeogenesis, fatty acid transport and signaling axis markers in the liver. The mRNA expression of markers for skeletal muscle synthesis, p7056k (P = 0.060) and GSK3B (P = 0.096), tended to be greater in cows from CON than SUP group. No differences were found for mRNA expression of markers for skeletal muscle degradation. We conclude that CP supplementation to CP-restricted late-pregnant beef cows reduces the maternal tissue mobilization and changes the profile of plasma circulating AA and the mRNA expression of markers for the synthesis of skeletal muscle tissue. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
121. Screening of a Soil Bacteria Collection for the Production of Alkali Thermostable Xylanases
- Author
-
Sampaio, C. R., primary, Silva, C. G. S., additional, Anjos, É. C. T., additional, Fernandes, R. P. M., additional, and Fernandes, M. F., additional
- Published
- 2018
- Full Text
- View/download PDF
122. Human introduction or natural dispersion? Atlantic Ocean occurrence of the Indo-Pacific whitetip reef sharkTriaenodon obesus
- Author
-
Bornatowski, H., primary, Loose, R., additional, Sampaio, C. L. S., additional, Gadig, O. B. F., additional, Carvalho-Filho, A., additional, and Domingues, R. R., additional
- Published
- 2018
- Full Text
- View/download PDF
123. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes
- Author
-
Bonifati V., Rohe C. F., Breedveld G. J., Fabrizio E., De Mari M., Tassorelli C., Tavella A., Marconi R., Nicholl D. J., Chien H. F., Fincati E., Abbruzzese G., Marini P., De Gaetano A., Horstink M. W., Maat Kievit J. A., Sampaio C., Antonini A., Stocchi F., Toni V., Guidi M., Dalla Libera A., Tinazzi M., De Pandis F., Fabbrini G., Goldwurm S., de Klein A., Barbosa E., Lopiano L., Martignoni E., Lamberti P., Vanacore N., Meco G., Oostra B.A., Italian Parkinson Genetics Network, MONTAGNA, PASQUALE, Bonifati V., Rohe C.F., Breedveld G.J., Fabrizio E., De Mari M., Tassorelli C., Tavella A., Marconi R., Nicholl D.J., Chien H.F., Fincati E., Abbruzzese G., Marini P., De Gaetano A., Horstink M.W., Maat-Kievit J.A., Sampaio C., Antonini A., Stocchi F., Montagna P., Toni V., Guidi M., Dalla Libera A., Tinazzi M., De Pandis F., Fabbrini G., Goldwurm S., de Klein A., Barbosa E., Lopiano L., Martignoni E., Lamberti P., Vanacore N., Meco G., Oostra BA., Italian Parkinson Genetics Network., and Clinical Genetics
- Subjects
Adult ,Male ,DNA, Complementary ,Adolescent ,Genotype ,Parkinson's disease ,assessment ,DNA Mutational Analysis ,Mutation, Missense ,Biology ,Early-onset parkinsonism ,medicine.disease_cause ,Genotype-phenotype distinction ,Cognitive neurosciences [UMCN 3.2] ,Gene Frequency ,PINK1 gene mutations ,medicine ,Missense mutation ,Humans ,Genetic Predisposition to Disease ,Genetic Testing ,Allele ,Age of Onset ,Child ,Allele frequency ,Genetics ,Mutation ,Parkinson'disease ,Genome ,Polymorphism, Genetic ,Sequence Homology, Amino Acid ,Parkinsonism ,Parkinson Disease ,Middle Aged ,medicine.disease ,Phenotype ,Italy ,Female ,Neurology (clinical) ,Age of onset ,Protein Kinases - Abstract
Item does not contain fulltext OBJECTIVE: To assess the prevalence, nature, and associated phenotypes of PINK1 gene mutations in a large series of patients with early-onset (
- Published
- 2005
124. Acute Behavioural Comparisons of Toluene and Ethanol in Human Subjects
- Author
-
Echeverria, Diana, Fine, L., Langolf, G., Schork, T., and Sampaio, C.
- Published
- 1991
125. Acute Neurobehavioural Effects of Toluene
- Author
-
Echeverria, Diana, Fine, L., Langolf, G., Schork, A., and Sampaio, C.
- Published
- 1989
126. Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations
- Author
-
Mestre, T.A., Duijn, E. van, Davis, A.M., Bachoud-Levi, A.C., Busse, M., Anderson, K.E., Ferreira, J.J., Mahlknecht, P., Tumas, V., Sampaio, C., Goetz, C.G., Cubo, E., Stebbins, G.T., Martinez-Martin, P., and MDS Comm Rating Scales Dev
- Subjects
behavior ,depression ,Huntington's disease ,irritability ,anxiety ,rating scales - Published
- 2016
127. Cirurgia nas varizes dos membros inferiores: Podemos preservar a veia safena magna?
- Author
-
Pereira Alves,C., Neves,J., Pinheiro,V., Moniz,L., Toscano,F., Figueiredo,J., Matias,R., Sampaio,C., Marques,A., Vieira,L., and Manso Neves,R.
- Subjects
eco-Doppler ,grande veia safena ,great saphenous vein ,veias varicosas ,varicose veins ,padrões de refluxo ,reflux patterns - Abstract
Introduction: Varicose veins are frequent and cause problems for patients and health care services. Varicose vein surgery is one of the three more frequent surgical procedures. Eco-Doppler observations have changed completely concepts of varicose veins beginning and progression with great reflex on clinical practice and treatment. Eco-Doppler as shown great saphenous vein (GSV) as an interfascial vein and not a superficial one, varicose veins with competent saphenofemoral junction as well as varicose veins just involving collaterals or collaterals with segments of GSV but not a continuous descending involvement of the GSV. Consequently two main patterns of venous reflux as been defined: the axial reflux with a continuous reflux of GSV trunk from groin to malleolus and the segmental reflux with reflux of segments of saphenous trunk but not a continuous descending reflux starting at the junction. This segmental reflux pattern presents in our practice three sub-types: sub-type 1, just involving superficial branches, sub-type 2, involving superficial branches plus segments of saphenous trunk and sub-type 3 with reflux of saphenofemoral junction plus tight collateral, with a non dilated GSV bellow the confluence of this collateral. Aim: Can we preserve the GSV when treating varicose veins with a segmental reflux pattern? Can we do a much lesser aggressive and quick surgery with equal or even better results as with classic surgery? Metolodgy: 54 consecutive patients with segmental reflux pattern operated on with phlebectomy of varicose superficial collaterals and with preservation of GSV. Clinical follow-up with symptomatic relieve, cosmetic results and no recurrence of varicose veins expressed as worthwhile surgery. Eco-Doppler follow - up expressed as: disappearance of previous segmental reflux of GSV, maintenance of previous reflux or progression of segmental reflux to an axial one. Mean follow-up time: 12,1 months. Results: Clinical results: 98,5 of patients consider surgery as worthwhile. Eco-Doppler results: 58% with no reflux, 40 % with maintenance of previous reflux and just 1 case (2%) with progression of reflux to an axial pattern. Conclusions: Clinical and eco-Doppler results of our study, support preservation of GSV when the pattern of reflux is a segmental one. The answer to our question: can we preserve the GSV is a positive yes we can. Our findings also support the concept that varicose veins are a local and multifocal process starting at any vein segment and not a progressive descending one starting at the sapheno-femoral- junction. Superficial varicose branches appear as main players and not the saphenous trunk as consider before. Introdução: As varizes dos membros inferiores são situação muito frequente causando problemas aos doentes e ao SNS. A cirurgia das varizes é das três mais frequentes cirurgias. As observações do exame eco-Doppler vieram revolucionar o conceito de aparecimento e progressão das varizes dos membros inferiores com reflexo no tratamento das mesmas. As observações do eco-Doppler mostraram a grande veia safena como uma veia interfascial e não superficial, veias varicosas com junção safeno femoral competente, bem como veias varicosas que envolvem somente veias colaterais ou veias colaterais e segmentos da grande veia safena, mas sem um envolvimento descendente progressivo desta veia a partir da juncao com a veia femural. Consequentemente foram definidos dois padrões principais de refluxo venoso: o refluxo axial com envolvimento contínuo descendente da grande veia safena desde a junção safenofemoral ao maléolo e o refluxo segmentar com envolvimento de segmentos da grande veia safena e/ou veias colaterais, mas sem continuidade descendente da GVS. O padrão de refluxo segmentar surge na nossa prática clinica com 3 subtipos: no subtipo 1 estão apenas refuxivos ramos superficiais, no subtipo 2 estão envolvidos ramos superficiais e segmentos da grande veia safena, mas sem refluxo descendente continuo da GVS e no subtipo 3 verifica-se refluxo ao nível da junção safenofemoral e de veias colaterais da coxa estando a GVS normal e sem refluxo abaixo da confluência da colateral varicosa. Objetivo: Na cirurgia das varizes dos membros inferiores com padrão de refluxo segmentar é possível proceder a simples flebectomias das colaterais varicosas preservando a GVS? ou seja proceder a uma cirurgia menos invasiva com iguais ou melhores resultados que a cirurgia clássica? Metodologia: Foram operados 54 doentes com padrão de refluxo segmentar com flebectomia das colaterais varicosas e preservação da grande veia safena. O seguimento clínico considerou o alívio sintomático e resultados cosméticos e a não recorrência de varizes, avaliados pela equipa cirúrgica e os doentes como cirurgia que valeu a pena. O seguimento por eco-Doppler classificou os refluxos segmentares prévios em: desaparecimento, persistência ou progressão para refluxo axial. O tempo médio de seguimento foi de 12,1 meses. Resultados clínicos: 98.5% dos doentes avaliaram a cirurgia como positiva. Resultados do Eco-Doppler: 58% com ausência de refluxo, 40% com persistência de refluxo e 1 caso (2%) com progressão do refluxo. Conclusão: Os resultados clínicos e seguimento por eco-Doppler, sustentam como possível a preservação da GVS nos doentes com padrão de refluxo segmentar. A resposta à questão: podemos preservar a GVS quando o refluxo é segmentar? é um sim podemos. Os nossos achados são também a favor do conceito de que as veias varicosas são um processo local e multifocal com início em qualquer segmento de veias colaterais ou safenas e não um processo descendente do tronco da safena com início na junção safenofemoral. As colaterais varicosas superficiais aparentam ter um papel de actor principal neste processo e não o tronco da veia safena, como considerado no conceito clássico.
- Published
- 2016
128. Multifaceted nanominerals and ultrafine particles in phosphogypsum: a by-product of coal cleaning rejects
- Author
-
De Leão, Felipe B., Waanders, F., Taffarel, S., Sampaio, C., Lima, B., and 10059571 - Waanders, Frans Boudewijn
- Published
- 2016
129. Friendly behavior” between two species of Myrichthys in Brazilian waters
- Author
-
Nunes, J. A. C. C., Maia-Nogueira, R., and Sampaio, C. L. S.
- Published
- 2007
- Full Text
- View/download PDF
130. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
- Author
-
Healy, Daniel G., Mario, Falchi, O'Sullivan, Sean S., Bonifati, Vincenzo, Alexandra, Durr, Susan, Bressman, Alexis, Brice, Jan, Aasly, Zabetian, Cyrus P., Stefano, Goldwurm, Ferreira, Joaquim J., Eduardo, Tolosa, Kay, Denise M., Christine, Klein, Williams, David R., Connie, Marras, Lang, Anthony E., Wszolek, Zbigniew K., Jose, Berciano, Schapira, Anthony H. V., Timothy, Lynch, Bhatia, Kailash P., Thomas, Gasser, Lees, Andrew J., Wood, Nicholas W., International Lrrk Consortium, Collaborators, Tazir, M., Ysmail Dahlouk, F., Belarbi, S., Hecham, N., Barbosa, E., Chien, H. F., Rieder, C. R., Jardim, L. B., Rogaeva, E., Lesage, S., Lohmann, E., Vidailhet, M., Bonnet, A. M., Agid, Y., Pollak, P., Tison, F., Durif, F., Broussolle, E., Berg, D., Hagenah, J., Gosal, D., Gibson, M., Vanacore, Nicola, Berardelli, Alfredo, Fabbrini, Giovanni, Fabrizio, E., Meco, Giuseppe, Stocchi, F., Dalla Libera, A., De Mari, M., Lamberti, P., Cossu, G., Pezzoli, G., Zini, M., Tesei, S., Zecchinelli, A., Sironi, F., Antonini, A., Mariani, C., Sacilotto, G., Meucci, N., Canesi, M., Di Fonzo, A., Oostra, B., Correia Guedes, L., Rosa, Mm, Coelho, M., Sampaio, C., Gaig, C., C. S., Lu, Wu Chou, Y. H., Quinn, N. P., Abou Sleiman, P. M., Muqit, M. M., Khan, N. L., Gandhi, S., Vaughan, J., Payami, H., Nutt, J. J., Factor, S. A., Higgins, D. S., Farrer, M. J., Hulihan, M., Brown, L., Mata, I. F., Samii, A., Yearout, D., Griffith, A., Leis, B. C., Roberts, J. W., Clinical Genetics, Department of Clinical Neurosciences, University College of London [London] (UCL)-Institute of Neurology, Genomic Medicine, Imperial College London-Kings College, Reta Lila Weston Institute for Neurological Studies, Queen Mary University of London (QMUL), Department of Clinical Genetics (DCG), Erasmus University Medical Centre, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Department of Neurology, Beth Israel Medical Centre- Albert Einstein College of Medicine [New York], St. Olav's Hospital, University of Washington [Seattle], Geriatric Research Education and Clinical Center, VA Puget Sound Health Care System, Parkinson Institute, Istituti Clinici di Perfezionamento, Neurological Clinic Research Unit, Institute of Molecular Medicine-Lisbon School of Medicine, Neurology Service, Institut Clinic Maltias del Sistema Nervios-Hospital Clinic Universitari-University of Barcelona, Division of Genetic Disorders, New York State Department of Health [Albany], University of Luebeck, Faculty of Medicine (Neurosciences), Monash University [Clayton], University of Toronto, Mayo Clinic Jacksonville, Service of Neurology, Centro de Investigacion Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III [Madrid] (ISC)-Instituto de Salud Carlos III [Madrid] (ISC), Mater Misericordiae University Hospital (The Mater Hospital), Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, Department of Neurodegenerative Diseases, Eberhard Karls Universität Tübingen = Eberhard Karls University of Tuebingen-Hertie-Institut for Clinical Brain Research, Department of Molecular Pathogenesis, UK Medical Research Council, UK Parkinson's Disease Society, UK Brain Research Trust, Internationaal Parkinson Fonds, Volkswagen Foundation, National Institutes of Health: National Institute of Neurological Disorders and Stroke and National Institute of Aging, Udall Parkinson's Disease Centre of Excellence, Pacific Alzheimer Research Foundation Centre, Italian Telethon Foundation, Fondazione Grigioni per il Morbo di Parkinson, Michael J Fox Foundation for Parkinson's Research, Safra Global Genetics Consortium, US Department of Veterans Affairs, French Agence Nationale de la Recherche., ANR-05-NEUR-0019,LRRK2 in PD,Pathologie moléculaire et modèles murins du gène LRRK2, impliqué dans la maladie de Parkinson(2005), Service de Génétique Cytogénétique et Embryologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Beth Israel Medical Centre- Albert Einstein College of Medicine, CIBER de Enfermedades Neurodegenerativas (CIBERNED), Mater Misericordiae University Hospital, Eberhard Karls Universität Tübingen-Hertie-Institut for Clinical Brain Research, ANR-05-NEURO-019,ANR-05-NEURO-019, and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
- Subjects
Gerontology ,Male ,Risk ,Pediatrics ,medicine.medical_specialty ,Parkinson's disease ,Genotype ,International Cooperation ,DNA Mutational Analysis ,Glycine ,Clinical Neurology ,Penetrance ,Disease ,Protein Serine-Threonine Kinases ,Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 ,Severity of Illness Index ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Serine ,Humans ,Genetic Predisposition to Disease ,Genetic Testing ,Age of Onset ,030304 developmental biology ,Genetic testing ,Family Health ,0303 health sciences ,medicine.diagnostic_test ,business.industry ,Case-control study ,Age Factors ,Parkinson Disease ,medicine.disease ,LRRK2 ,3. Good health ,nervous system diseases ,Dyskinesia ,Case-Control Studies ,[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,Female ,Neurology (clinical) ,genetics ,parkinson ,Age of onset ,medicine.symptom ,business ,030217 neurology & neurosurgery - Abstract
Summary Background Mutations in LRRK2 , the gene that encodes leucine-rich repeat kinase 2, are a cause of Parkinson's disease (PD). The International LRRK2 Consortium was established to answer three key clinical questions: can LRRK2 -associated PD be distinguished from idiopathic PD; which mutations in LRRK2 are pathogenic; and what is the age-specific cumulative risk of PD for individuals who inherit or are at risk of inheriting a deleterious mutation in LRRK2 ? Methods Researchers from 21 centres across the world collaborated on this study. The frequency of the common LRRK2 Gly2019Ser mutation was estimated on the basis of data from 24 populations worldwide, and the penetrance of the mutation was defined in 1045 people with mutations in LRRK2 from 133 families. The LRRK2 phenotype was defined on the basis of 59 motor and non-motor symptoms in 356 patients with LRRK2 -associated PD and compared with the symptoms of 543 patients with pathologically proven idiopathic PD. Findings Six mutations met the consortium's criteria for being proven pathogenic. The frequency of the common LRRK2 Gly2019Ser mutation was 1% of patients with sporadic PD and 4% of patients with hereditary PD; the frequency was highest in the middle east and higher in southern Europe than in northern Europe. The risk of PD for a person who inherits the LRRK2 Gly2019Ser mutation was 28% at age 59 years, 51% at 69 years, and 74% at 79 years. The motor symptoms (eg, disease severity, rate of progression, occurrence of falls, and dyskinesia) and non-motor symptoms (eg, cognition and olfaction) of LRRK2 -associated PD were more benign than those of idiopathic PD. Interpretation Mutations in LRRK2 are a clinically relevant cause of PD that merit testing in patients with hereditary PD and in subgroups of patients with PD. However, this knowledge should be applied with caution in the diagnosis and counselling of patients. Funding UK Medical Research Council; UK Parkinson's Disease Society; UK Brain Research Trust; Internationaal Parkinson Fonds; Volkswagen Foundation; National Institutes of Health: National Institute of Neurological Disorders and Stroke and National Institute of Aging; Udall Parkinson's Disease Centre of Excellence; Pacific Alzheimer Research Foundation Centre; Italian Telethon Foundation; Fondazione Grigioni per il Morbo di Parkinson; Michael J Fox Foundation for Parkinson's Research; Safra Global Genetics Consortium; US Department of Veterans Affairs; French Agence Nationale de la Recherche.
- Published
- 2008
- Full Text
- View/download PDF
131. Morphological characterization of ckd in cats: Insights of fibrogenesis to be recognized
- Author
-
Morais, G. B., primary, Viana, D. A., additional, Verdugo, J. M., additional, Roselló, M. G., additional, Porcel, J. O., additional, Rocha, D. D., additional, Xavier Júnior, F. A. F., additional, Barbosa, K. D. S. M., additional, Silva, F. M. O., additional, Brito, G. A. C., additional, Sampaio, C. M. S., additional, and Evangelista, J. S. A. M., additional
- Published
- 2017
- Full Text
- View/download PDF
132. [PP.11.29] CARDIOVASCULAR RISK PROFILE IN A FAMILY HEALTH PROGRAM IN RIO DE JANEIRO – A PILOT PROJECT
- Author
-
Santos, T. Lorena Dos, primary, Lobão, M.B., additional, Santana, J. Prado, additional, Paula, E. Louysi D., additional, Ruschel, M. Roveda, additional, Hermsdorff, C. Freitas, additional, Cunha, M. Loureiro, additional, Rozemberg, L. Bom, additional, Tostes, C. Nessimian, additional, Mayer, T. Amado, additional, Barata, C. Pavani, additional, Santana, L. Oliveira, additional, Oliveira, T. Santos, additional, Silva, L. Fernandes Da, additional, Lima, J. Barros De, additional, Fontes, L. Flores, additional, Carvalho, A. Nunes, additional, Sampaio, C., additional, Fuchs, R.J. Povoleri, additional, and Muxfeldt, E.S., additional
- Published
- 2017
- Full Text
- View/download PDF
133. [PP.28.08] THE STOP-BANG QUESTIONNAIRE AND EPWORTH SLEEPINESS SCALE AS A SCREENING TOOL FOR OBSTRUCTIVE SLEEP APNEA IN A FAMILY HEALTH PROGRAM IN RIO DE JANEIRO – A PILOT PROJECT
- Author
-
Furriel, A., primary, Lapenta, M., additional, Rosenbrock, B., additional, Franco, A.L. Braga, additional, Santos, T. Lorena Dos, additional, Forgiarini, L. Reis, additional, Lobão, M.B., additional, Santana, L. Oliveira, additional, Oliveira, T. Santos, additional, Oliveira, M. Guimarães De, additional, Ribeiro, C. Paiva, additional, Nogueira, N. Faquer, additional, Sampaio, C., additional, Santana, J. Prado, additional, Mayer, T. Amado, additional, Maia, R. Bittencourt, additional, Ayres, A. Bergamo, additional, Barata, C. Pavani, additional, Hermsdorff, C. Freitas, additional, and Muxfeldt, E., additional
- Published
- 2017
- Full Text
- View/download PDF
134. 293 Nutritional evaluation of forage ephedra (Ephedra nevadensis) as an alternative forage using a dual-flow continuous culture system
- Author
-
Sampaio, C. B., primary, Marostegan de Paula, E., additional, Galoro da Silva, L., additional, Brandao, V., additional, Dai, X., additional, Shenkoru, T., additional, Perryman, B., additional, and Faciola, A., additional
- Published
- 2017
- Full Text
- View/download PDF
135. 577 In vitro ruminal fermentation and enteric methane production of tropical forages supplemented with nitrogen or the combination of nitrogen and starch
- Author
-
Cardozo, M. A., primary, Sampaio, C. B., additional, Detmann, E., additional, Vargas, A. N. Z., additional, and Fonseca, M., additional
- Published
- 2017
- Full Text
- View/download PDF
136. Practical Difficulties Associated with the Indian Coal Washeries: A Case Study
- Author
-
Mohanta, S., primary, Sahoo, B., additional, Sampaio, C. H., additional, and Petter, C. O., additional
- Published
- 2017
- Full Text
- View/download PDF
137. Polarization microscopy as a tool for quantitative evaluation of collagen using picrosirius red in different stages of CKD in cats
- Author
-
Morais, G. B., primary, Viana, D. A., additional, Silva, F. M. O., additional, Xavier Júnior, F. A. F., additional, Farias, K. M., additional, Pessoa, C. D'Ó, additional, Silveira, J. A. M., additional, Alves, A. P. N. N., additional, Mota, M. R. L., additional, Silva, F. D. O., additional, Sampaio, C. M. S., additional, Verdugo, J. M. G., additional, and Evangelista, J. S. A. M., additional
- Published
- 2017
- Full Text
- View/download PDF
138. Effect of protein supplementation in the rumen, abomasum, or both on intake, digestibility, and nitrogen utilisation in cattle fed high-quality tropical forage
- Author
-
Batista, E. D., primary, Detmann, E., additional, Gomes, D. I., additional, Rufino, L. M. A., additional, Paulino, M. F., additional, Valadares Filho, S. C., additional, Franco, M. O., additional, Sampaio, C. B., additional, and Reis, W. L. S., additional
- Published
- 2017
- Full Text
- View/download PDF
139. Protocol for the Development of Standard of Practice Guides for the Symptomatic Treatment of Huntington Disease
- Author
-
Anderson, K.E., Craufurd, D., Drazinic, C., Duijn, E. van, Edmondson, M., Kammen, D. van, Loy, C., Priller, J., Sampaio, C., Yohrling, G., Goodman, N., and Goodman, L.V.
- Published
- 2015
140. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
- Author
-
Bonaca, MP, Bhatt, DL, Cohen, M, Steg, PG, Storey, RF, Jensen, EC, Magnani, G, Bansilal, S, Fish, MP, Im, K, Bengtsson, O, Ophuis, TO, Budaj, A, Theroux, P, Ruda, M, Hamm, C, Goto, S, Spinar, J, Nicolau, JC, Kiss, RG, Murphy, SA, Wiviott, SD, Held, P, Braunwald, E, Sabatine, MS, Morin, S, Dantzer, E, Acquilano, D, McGuire, RL, Gannon, JB, Gershman, E, Ahlbom, AM, Boberg, B, Abola, MT, Ardissino, D, Aylward, P, Corbalan, R, Dalby, A, Diaz, R, Hu, DY, Isaza, D, Kamensky, G, Kiss, R, Kontny, F, Lopez-Sendon, J, Medina, F, Montalescot, G, Nicolau, J, Paolasso, E, Parkhomenko, A, Van De Werf, F, Anderson, JL, White, HD, Verheugt, FWA, Pedersen, TR, DeMets, DL, Lowe, C, Arevalo, C, Awtry, E, Berger, C, Croce, K, Desai, A, Gelfand, E, Ho, C, Leeman, D, Link, M, Norden, A, Pande, A, Rost, N, Ruberg, F, Silverman, S, Singhal, A, Vita, J, Alvarisqueta, A, De Gennaro, N, Berli, M, Roude, AE, Di Gennaro, JA, Albisu, JF, Caccavo, A, Torres, M, Cuadrado, J, Bordoni, P, Cuello, J, Aviles, A, Glenny, A, Recoaro, R, Fernandez, R, Strada, BN, Fuentealba, V, Gallo, C, Duran, RG, Garcia, C, Hominal, M, Castoldi, M, Jure, H, Pacora, FF, Lorenzatti, A, Martinez, JM, Macin, S, Cocco, N, MacKinnon, I, Bagnato, MB, Marino, J, Cusimano, S, Arias, V, Focaccia, M, Muntaner, J, Mansilla, V, Poy, C, Prado, A, Paterlini, G, Montana, O, Camino, A, Sala, J, Luciani, C, Vico, M, Morell, Y, Dumont, C, Vottero, E, Zangroniz, P, Lescano, A, Morara, P, Marquez, LL, Patron, FR, Labarta, GB, Sivila, CD, Quiroga, AR, Maffei, L, Sassone, S, Rolandi, F, Vesentini, N, Carnero, G, Del Verme, S, Hershson, A, Figal, JC, Viso, ME, Hii, C, Smith, K, Singh, B, Acampo, M, Rogers, J, ODonoghue, M, Amerena, J, Long, A, Dart, A, Kay, S, Worthley, M, Nimmo, J, Lehman, R, Morrison, H, Dick, R, Savage, C, van Gaal, W, Park, M, Blombery, P, McCarthy, C, Oqueli, E, Hill, D, Sader, M, Vrachas, D, Purnell, P, Vibert, J, Collins, N, Gordon, A, Arstall, M, Rose, J, Aroney, C, Cleave, P, Fitzpatrick, M, Mackenzie, M, Garrahy, P, Hall, C, Nelson, G, Reid, E, Lee, A, Gibbs, J, Thompson, P, Crittenden, J, Hammett, C, Hindom, L, Antonis, P, Manzoney, A, Cross, D, Pollard, C, Brieger, D, Wu, J, Whelan, A, Tulloch, G, Taylor, A, Smith, B, Horowitz, J, Black, M, Boland, J, Malmendier, D, Celen, H, Wendelen, E, Claeys, M, Pieter, M, Cools, F, Simons, N, De Maeseneire, S, De Wolf, L, Brike, C, Dubois, P, Bolado, ACY, Foading-Deffo, B, Tahon, S, Friart, A, Arend, C, Gevaert, S, Verdegem, P, Marechal, P, Gits, F, Pierard, L, Celentano, C, Pirenne, B, Bouvy, C, Renkin, J, Huyberechts, D, Sinnaeve, P, De Velder, L, Stammen, F, Casier, T, Striekwold, H, Van den Broeck, D, Thoeng, J, Goris, R, Timmermans, P, Collard, SJ, Van De Borne, P, De Clippel, M, Wollaert, B, Jacobs, C, Vankelecom, B, Daelemans, Y, Vervoort, G, Drieghe, S, Vranckx, P, Janssen, A, Vrolix, M, Simenon, I, Wijns, W, Delacroix, H, Denie, D, Schoors, D, Lemoine, I, Cornelis, K, Willems, AM, Schroder, E, Domange, J, Greque, G, Machado, H, Armaganijan, D, Del Monaco, MI, da Silva, D, Nakazone, R, Dutra, O, Vaz, R, Daher, R, Rodrigues, D, Guimaraes, A, Teixeira, A, Saraiva, J, Leaes, P, Blacher, M, Maia, L, Nakazone, MA, Manenti, E, Ruschel, K, Marin-Neto, J, Pavao, R, Preto, R, Junior, AA, Oliveira, G, Rassi, S, Sampaio, D, Rossi, PR, dos Santos, L, de Souza, J, Lino, E, Filho, PP, Zucchetti, C, Gomes, M, de Paiva, A, Sousa, AC, Almeida, A, Botelho, R, da Silva, R, Giraldez, R, Franken, M, Faludi, A, Bertolami, M, Hernandes, M, Lucas, N, Carvalho, A, Bertolami, A, Precoma, D, Geralde, L, Pereira, A, Cesar, L, Mioto, B, Marino, R, Rabelo, W, dos Santos, F, Vidotti, M, Mangione, J, Mauro, M, Kormann, A, Ultramari, F, Zimmermann, S, Michalaros, Y, Fonseca, M, Sampaio, C, Eliaschewitz, F, Barbosa, E, Drews, C, de Lorenzo, A, Barros, C, Cancado, G, Neuesnchwander, F, Zimmermann, E, Chompalova, B, Denchev, S, Gocheva, N, Mihov, A, Mincheva, V, Gelev, V, Tisheva, S, Todorov, G, Goudev, A, Parvanova, Z, Todorova, M, Mitkova, M, Smilov, L, Yakovova, S, Milanova, K, Aleksov, N, Mollov, M, Shishmanova, D, Hristova, K, Uzunangelov, Y, Peltegov, V, Karamitev, G, Benov, H, Vasileva, D, Parishev, G, Milcheva, N, Avramov, D, Miteva, B, Stoyanovski, V, Pencheva, G, Nikolova, L, Stancheva, N, Nyagina, M, Markov, D, Spirova, D, Peneva, Y, Peshkov, O, Mitkova, L, Mandzhukova, S, Rangelova, V, Ivanov, K, Krusheva, B, Raycheva, V, Gergova, V, Goranov, K, Stoykov, A, Staleva, M, Rashkova, V, Postadzhian, A, Krancheva, V, Lulova, E, Delchev, G, Cantor, W, Constance, C, Gosselin, G, Marr, D, Pandey, A, Pesant, Y, Pouliot, J, Gladstone, P, McPherson, T, Rupka, D, Saw, J, St-Amour, E, Syan, G, Syan, R, Rosenbloom, A, Vizel, S, Della Siega, A, Halperin, F, Nigro, F, Chehayeb, R, Fell, D, Labonte, R, Nawaz, S, Gupta, M, Ma, P, Glanz, A, Kouz, S, Bhargava, R, Dion, D, Dupuis, R, Grondin, F, Wong, B, Sabbah, E, Hui, W, Belisle, P, Tymchak, W, Montigny, M, Lonn, E, Bose, S, Kincade, D, Gallo, R, Lamy, A, Bell, A, Lemay, M, Bata, I, Kostuk, W, Cheung, S, Petrella, R, Lubelsky, B, Berlingieri, J, Fortin, C, DeYoung, J, Babapulle, M, Landry, D, Gupta, A, Bertrand, O, Jadin, M, Robbins, K, Gauthier, MF, Masson, C, Reyes, V, O'Blenis, G, Clarus, S, Sardin, V, Marquette, S, Bozek, B, Spurrell, D, Thiessen, S, Fox, R, Tremblay, I, Singh, J, Samms, S, Ross, B, Solomon, P, Nelson, S, Roberts, P, Forsyth, C, Lepage, C, McPherson, C, Dewar, C, Dela Cruz, C, Louch, D, Vilag, C, Roy, M, Stata, C, Morissette, A, Ouimet, F, Bilodeau, N, Chausse, I, Kvill, L, Chartrand, MJ, Harris, L, Bolduc, H, Magi, A, Jule, P, Valley, S, Morrissette, J, Power, P, Kailey, P, Thomas, A, Wright, D, Carr, S, Cleveland, T, Dihel, C, Coldwell, J, Schellenberg, S, Viau, C, Watt, M, Corke, R, Shea-Landry, G, Gandhi, A, Tishler, S, Prieto, JC, Noriega, V, Cobos, L, Obreque, C, Potthof, S, Zapata, J, Lucero, F, Luque, M, Pincetti, C, Torres, G, Yanez, M, Vasquez, C, Manriquez, L, Espinoza, MJ, Yovaniniz, P, Grandon, M, Castro, P, Llevaneras, S, Lanas, F, Hidalgo, J, Arriagada, G, Villan, C, Florenzano, F, Chacon, MV, Rodriguez, M, Barreda, B, Raffo, C, Reyes, T, Hu, D, Liu, W, Tan, N, Feng, Y, Dong, Y, Yang, D, Liao, Y, Wei, F, Wei, M, Yan, M, Yan, X, Wang, S, Li, Y, Yuan, Z, Xiong, Y, Zhu, J, Li, S, Ma, G, Chen, L, Li, Z, Liu, Y, Xiong, W, Pang, W, Chen, Y, Lu, G, Chen, Z, Zhao, S, Zhou, H, Huang, J, Gang, Y, Chai, Y, Yang, X, Zhang, Z, Mu, Z, Hernandez, E, Mora, C, Maria, E, Catalan, Y, Reynales, H, Huertas, D, Molina, D, Rendon, N, Sanchez, G, Tellez, R, Botero, R, Salazar, P, Vesga, B, Delgado, P, Herrera, M, Perez, D, Jaramillo, N, Toloza, R, Orozco, A, Bustamante, Y, Jaramillo, C, Garces, G, Saaibi, J, Castillo, J, Arana, C, Gonzalez, M, Urina, M, Ramirez, N, Manzur, F, Rosales, D, Quintero, A, Gonzalez, E, Accini, J, Reyes, M, Elbl, L, Malecha, J, Stanek, L, Jerabek, O, Lubanda, H, Kos, P, Zidkova, E, Vlckova, D, Naplava, R, Ludka, O, Ludkova, A, Soucek, M, Kuchar, J, Poloczek, M, Wasserburger, B, Panovsky, R, Linhart, A, Rihacek, I, Macha, J, Grunfeldova, H, Spinarova, L, Zanova, M, Bren, J, Zarembova, J, Cermak, O, Sembera, Z, Svobodova, I, Monhart, Z, Pleva, L, Sipula, J, Polasek, R, Kolmas, P, Dedek, V, Janota, T, Stipal, R, Kucera, D, Bednarova, J, Broulova, P, Lukac, M, Hanak, P, Reichert, P, Bouchal, P, Turkova, N, Krocova, E, Petrova, I, Matyasek, I, Brychta, T, Machova, V, Marusincova, I, Sperlingova, B, Macquin-Mavier, T, Khalife, K, Galley, D, Elhadad, S, Decoulx, E, Cottin, Y, Coisne, D, Bonnet, JL, Ferrari, E, Range, G, Cayla, G, Goralski, M, Furber, A, Elbaz, M, Aboyans, V, Poulard, JE, Zemour, G, Labeque, JN, Hirsch, JL, Vaquette, B, Livarek, B, Igigabel, P, Lafitte, S, Oudghiri, M, Bertin, B, Beitar, T, Merkling, D, Beltra, C, Maubert, A, El Jarroudi, M, Bichat, F, Berger, N, Fiacchetti, C, Douillet, M, Laure, C, Leperchois-Jacquey, C, Miran, S, Cornet, C, Rosolin, N, Pradel, V, Leparree, S, Doux, N, Mais, C, Sevilla, J, Laurencon, V, Georges, J, Gilard, V, Duprat, C, Giannitsis, E, Schenkenberger, I, Appel, KF, Toursarkissian, N, Bott, J, Nischik, R, Schmidt, E, Jung, T, Steiner, S, Khariouzov, A, Heuer, H, Kadel, C, Hanefeld, M, Weil, J, Koenig, W, Horacek, T, Muenzel, T, Brachmann, J, Weber, D, Wittlich, N, Stellbrink, C, Dungen, HD, Leschke, M, Zeymer, U, Dorsel, T, Voehringer, HF, Dissmann, M, Vom Dahl, J, Derwahl, KM, Trenk, D, Frey, N, Schroeder, T, Foerster, A, Bartels, R, Kisselbach, C, Deigentasch, H, Dreykluft, K, Becker, P, Scheuren, A, Erdas, M, Wipper, J, Schmidt, A, Henzler, A, Winter, K, Fischer, S, Kopf, S, Laschewski, B, Rahn, G, Schrapel, C, Miodek, M, Hildenbrand, S, Fink, P, Gebel, G, Goebel, U, Siepmann, C, Drexler, A, Maiwald, A, Blaich, B, Baumann, S, Iselt, M, Gebhardt, S, Kazcmarek, N, Krug-Hoeren, B, Traubler, B, Nicula, D, Reichenbach, D, Langer, C, Kiroglu, K, Riedel, S, Schulte, M, Borst, M, Katona, A, Vertes, A, Merkely, B, Ungi, I, Kiraly, C, Zolyomi, S, Horvath, I, Lupkovics, G, Edes, I, Simon, E, Czuriga, I, Laszlo, Z, Kancz, S, Takacs, J, Papp, A, Czigany, A, Muller, G, Tas, AS, Polgar, P, Jilling, MJ, Bartal, G, Kerkovits, A, Bodi, M, Benczur, B, Valco, J, Erdei, F, Sebo, J, Korda, A, Turi, T, Becker, D, Kalapos, A, Bosko, M, Pap, G, Magyari, B, Basa, A, Jenei, C, Bakai, J, Unterberger, K, Vas, K, Fulop, G, Nagy, M, Takacs, A, Mate, Z, Szilagyi, A, Nagy, K, Svab, M, Kis, E, Horthy, R, Kantor, F, Sperr, E, Bajcsi, E, Bujdoso, A, Martina, P, Fiscella, A, Marenzi, G, Tamburino, C, Terrosu, P, Presbitero, P, Cuccia, C, Bovenzi, F, Berti, S, Colivicchi, F, Paloscia, L, Scherillo, M, Tartaglione, S, Della Rovere, F, De Cesare, N, Manari, A, Astarita, C, Oltrona, L, Marzilli, M, Caldarola, P, Merlini, P, Celentano, A, Di Sciascio, G, Pajes, G, Silvestri, O, Delfino, R, Bassani, F, Cavallini, C, Fattore, L, Di Lorenzo, L, Notarangelo, F, Stefanin, C, Giacoppo, M, Rubino, M, Dammino, L, Chessa, P, Di Pizzo, A, Musmeci, G, Mazzoni, A, Tyack, K, Aiello, A, Mascellanti, M, Formigli, D, Guglielmino, G, Bernabo, P, Bocciarelli, M, De Iaco, G, Russo, G, Rizzotti, D, Orsini, E, Saponetti, LS, Babbolin, M, De Divitiis, M, Patti, G, Monti, F, Silvestri, N, Valbusa, A, Lazzarotti, M, Puccetti, L, Grikstaite, E, Patrizi, G, Bosco, B, Marchegiano, R, Takenaka, T, Ono, M, Suzuki, M, Hasegawa, K, Domae, H, Fukui, K, Iseki, H, Aoyama, T, Suzuki, C, Sakai, R, Hashimoto, T, Inoko, M, Sasaki, T, Kataoka, T, Okutsu, M, Yasaka, Y, Miyamoto, T, Tomobuchi, Y, Tamura, R, Hosokawa, S, Komura, Y, Takahashi, N, Mima, T, Sadamatsu, K, Fujimoto, K, Matsumura, T, Koide, S, Himi, T, Hashimoto, Y, Yamasaki, M, Okubo, M, Takase, H, Morii, I, Utsu, N, Higashino, Y, Shigematsu, S, Nakagawa, T, Ota, T, Takahashi, W, Kakishita, M, Hayashi, Y, Momiyama, Y, Baden, M, Saeki, T, Hiroi, S, Wada, A, Nakata, A, Nishi, Y, Hirasawa, S, Shibata, Y, Fukuzawa, S, Machida, M, Takama, N, Teranishi, J, Sakuma, K, Abe, Y, Suzuki, A, Yamazaki, A, Nakachi, T, Nagayama, H, Fujino, S, Tsurukai, A, Nojima, S, Ishiguchi, Y, Hada, K, Nakatani, K, Yamamoto, K, Matsuo, A, Yamaguchi, E, Ito, S, Matsuda, M, Onishi, M, Kawanishi, Y, Ohashi, Y, Ochi, K, Miyamoto, S, Ichishita, Y, Iwamoto, H, Sagara, Y, Komori, M, Matsumura, A, Nakashima, R, Kondo, M, Suzuki, K, Kodama, S, Kotajima, H, Fujimoto, N, Honda, K, Iwamoto, M, Okada, S, Ichinose, K, Takinami, N, Takagi, E, Nakano, A, Tomari, H, Yokoyama, T, Matsui, Y, Nishimura, N, Asano, T, Mochiduki, A, Yamashita, S, Okino, S, Hirabayashi, K, Funada, R, Wardeh, AJ, Dille, C, De Melker, EC, van der Spoel, A, Willems, FF, Maassen, E, Westendorp, ICD, Zweers, D, Dunselman, PHJM, Blom, L, Ronner, E, Wissenburg, A, van der Sluis, A, Badings, EA, den Hartog, FR, Singerling, M, Aksoy, I, Heil, A, Tjeerdsma, G, van Daalen, C, Lenderink, T, Lardenois, R, Prins, FJ, Rutten, R, Plomp, J, Veldmeijer, S, De Vries, RJM, Krikken, J, Ophuis, TAJMO, Buvelot, S, Bos, RJ, Tan-Urgert, B, Werner, HA, Wittekoek, M, van Daele, MERM, Bouwens, M, Oomen, A, Meijlis, P, Verheul, JA, Uiterwaal, H, Knufman, N, de Lange, H, Bartels, GL, Hendriks-Van Woerden, M, van Bemmel, B, Beyering, M, Zwart, PAG, Teng, Y, van der Zwaan, C, Havenaar, J, Hermans, WRM, de Graauw, J, Hamraoui, K, Dabrowska, K, de Nooijer, C, Groenenberg, I, Kietselae, BLJH, Muis, L, Hamer, BJB, Hobe, C, van Eck, JWM, Elzebroek, N, Tans, JGM, Stapel, AGT, Nierop, PR, Dirks, M, Kuijper, AFM, Schiks, M, de Groot, MR, Post, G, ten Berg, JM, Bras, R, Koolen, JJ, van Leur, L, Herrman, JPR, Roelse, A, Ebink, C, Jones, B, Lipsic, E, Couperus, M, Bogaard, K, Dijk, A, Pettersen, KI, Fortun, M, Gullestad, L, Stueflotten, W, Popovic, I, Sobye, ET, Hogalmen, G, German, M, Hysing, J, Flagstad, E, Slettom, G, Nordrehaug, JE, Isaksen, A, Graven, T, Haug, H, Sandvik, J, Thunhaug, H, Ronning, PB, Gravrok, B, Lappegard, KT, Enebakk, T, Ronnevik, P, Ronnevik, T, Hurtig, U, Skanke, E, Omland, T, Tobiassen, GM, Berrospi, P, Ragas, Y, Bustamante, G, Marruffo, Y, Chavez, E, Chaname, A, Heredia, J, Gamero, K, Lema, J, Carrion, AM, Rodriguez, V, Cabanillas, N, Rodriguez, A, Zena, N, Segura, L, Rojas, C, Toce, L, Carrera, J, Orihuela, B, Del Portal, M, Roldan, Y, Roldan, G, Rodriguez, J, Chavez, C, Luna, G, Parra, J, Ramos, J, Mogrovejo, W, Godoy, J, Talledo, MZ, Diestra, J, Godoy, A, Matta, M, Pino, C, Vergara, R, Chois, A, Guillen, AM, Medina, J, Chirinos, J, Paredes, A, Quiroz, M, Camacho, L, Gil, M, Cerbito, S, Beltran, J, Tanglao, M, Uy, N, Busa, J, Rogelio, G, Arbis, MG, Prado, JP, Miranda, M, Sulit, DJ, Dioquino, R, Sevilla, R, Soriano, RA, Rosita, RR, Amazona, A, Atilano, A, Lim, E, Ebo, G, Maglasang, P, Palmes, P, Loreno, CA, Tirador, L, Alagban, C, Roxas, DJ, Roxas, JF, Cheng, F, De Guzman, S, Morales, D, Mararac, T, Barbas, B, Barbas, K, Ferrolino, A, Baysac, C, Llarena, AC, Julianes, C, Torun, A, Dalkowski, M, Widejko, K, Derlaga, B, Laskowska, E, Dudek, D, Dziewierz, A, Jozwa, R, Busz-Papiez, B, Pawlowicz, L, Kaczmarczyk, M, Jaworska, K, Skonieczny, G, Kopaczewski, J, Wujkowski, M, Krasowski, W, Krzyzanek, P, Kubica, J, Kozinski, M, Miekus, P, Glaza, M, Podolec, P, Wilkolek, P, Piepiorka, M, Piepiorka-Broniecka, M, Pluta, W, Ploch, M, Rynkiewicz, A, Mosakowska, K, Szpajer, M, Lesinski, D, Szwed, H, Jasek, S, Sciborski, R, Piotrowicz, R, Musial, W, Lisowska, A, Rekosz, J, Kasznicka, M, Korzeniak, R, Staneta, P, Konczakowski, P, Waluszek-Konczakowska, I, Cymerman, K, Lubinski, A, Grycewicz, T, Hiczkiewicz, J, Plucinski, M, Korol, M, Szczech, J, Hawro, M, Skorski, M, Cichon, K, Jankowski, M, Cygler, J, Ottomanska-Cygler, M, Korecki, J, Gulaj, E, Zechowicz, T, Zechowicz, M, Goch, A, Topolinski, B, Ogorek, M, Szczepanska, A, Wojewoda, P, Jagoda, E, Krzyzanowski, W, Muzyk-Osikowicz, M, Jaszczurowski, W, Stasiewski, A, Wietrzynska, J, Miklaszewicz, B, Beme, A, Sudnik, W, Matys, U, Ponikowski, P, Powierza, S, Kim, YH, Choi, DJ, Seung, KB, Lim, DS, Lee, SH, Kim, HS, Bae, JH, Hong, TJ, Hong, MK, Tahk, SJ, Kim, YJ, Yoon, J, Jeong, MH, Chae, JK, Cho, MC, Hong, SK, Hur, SH, Jeong, JO, Her, SH, Lee, JM, Chang, KC, Yoon, CH, Chang, K, Park, J, Choi, S, Park, K, Bae, Y, Lee, H, Kim, BK, Yoon, MH, Park, JS, Jang, H, Kim, C, Cho, EJ, Bae, J, Lee, D, Lee, J, Choi, YY, Dimulescu, D, Vintila, M, Fruntelata, A, Pirvu, O, Stanciulescu, G, Giuca, A, Militaru, C, Radoi, M, Bobescu, E, Crisu, D, Creteanu, M, Minescu, B, Bolohan, F, Manitiu, I, Bengus, C, Iosipescu, L, Ciobotaru, V, Basarab, G, Benedek, I, Constantinescu, M, Cristea, M, Capalneanu, R, Tatu-Chitoiu, G, Huidu, S, Protopopescu, L, Greavu, M, Diaconu, M, Blajan, D, Istratoaie, O, Lican, G, Bisoc, A, Doka, B, Jemna, D, Parasteac, M, Serban, L, Mihai, M, Cioca, G, Ochean, V, Costache, L, Andor, M, Stoica, D, Benedek, T, Sava, N, Anciu, M, Mot, S, Cornaciu, S, Boldueva, S, Golitsyn, S, Karpov, Y, Kobalava, Z, Konstantinov, V, Kuimov, A, Ezhov, M, Panov, A, Novikova, T, Simanenkov, V, Smolenskaya, O, Tsyba, L, Vishnevsky, A, Yakhontova, P, Kislyak, O, Demchenko, E, Yakovlev, A, Ermoshkina, L, Arkhipov, M, Galyavich, A, Strongin, L, Kosmacheva, E, Goloshchekin, B, Sidorenko, B, Izmozherova, N, Shustov, S, Orlikova, O, Lukyanov, Y, Koziolova, N, Nedogoda, S, Statsenko, M, Kotelnikov, M, Osipenko, M, Oshchepkova, E, Bolieva, L, Ryamzina, I, Pavlysh, E, Samokhvalova, M, Mironova, N, Buza, V, Shavarov, A, Serebrenitskaya, M, Khomyakova, L, Safarova, M, Lohovinina, N, Staroverov, I, Bitakova, F, Zakharova, N, Khurs, E, Belenky, D, Kositsyn, D, Rovnykh, Y, Kasatova, T, Lubinskaya, E, Omelchenko, M, Slukhaenko, I, Kozulin, A, Baleeva, L, Pochinka, I, Kizhvatova, N, Laptev, I, Bugrimova, M, Popov, A, Kovalevskaya, E, Orlikov, E, Paltsman, Z, Lamden, D, Surovtseva, M, Tsoma, V, Derevjanchenko, M, Streltsov, S, Bikbulatova, E, Dmitriev, V, Byazrova, S, Khovaeva, Y, Komandenko, O, Dlesk, A, Urban, M, Vinanska, D, Dzupina, A, Hranai, M, Cisar, P, Toth, P, Paulov, S, Sivak, V, Bolvanska, N, Pella, D, Palka, J, Nedelova, I, Benacka, J, Gergel, V, Hatalova, K, Kohut, P, Kovar, F, Knazeje, M, Macek, V, Sinska, R, Bugan, V, Badenhorst, JCW, Erasmus, L, Burgess, LJ, de Necker, I, Corbett, CH, Fouche, L, Dawood, SY, Conradie, C, Delport, EF, Kruger, M, Ebrahim, I, Bobak, C, Nethononda, MR, Nunkoo, T, van Rensburg, FPJ, Middle, R, Horak, AR, Henley, L, Mabin, TA, King, A, Ranjith, N, Ramdas, S, Roodt, A, Coetsee, E, Theron, H, Karsten, M, Van Zyl, LJ, Roscher, M, Venter, TP, de Kock, L, Becker, AC, Swanepoel, J, Ismail, SM, Dalby, AJ, Allman, J, Roux, JP, Christie, H, Naidoo, DP, Vawda, GHM, Manga, P, Olckers, W, Mpe, MT, Farrell, BM, Areses, ELD, Lopez, SV, Fernandez, JMC, Roldan, JG, Pavia, PG, Segovia, AG, Puig, JG, Garcia, VC, Aguilera, RM, Munoa, MD, Cortada, JB, Cereto, PC, Perez, IP, Cid, LP, Basilio, EG, Guerra, PC, Ortiz, AF, Balcones, LDV, Vera, TR, Martinez, JMG, Galvan, ED, Caballero, AH, Blanco, VMR, Lopez, JMR, Franco, MRP, Soriano, FR, Porcar, LC, Fillat, ARC, Moreno, SG, Montejano, MG, Guerrero, JMD, Coronado, JLB, Eizagaechevarria, NM, Araucua, GN, Rubio, AM, Roca, MC, Marimon, XGM, Perales, MV, Gonzalez, AB, Sastre, MP, Juanatey, JRG, Acuna, JMG, Al-Khalili, F, Lof, P, Bandh, S, Myllyla, L, Christensen, K, Johansson, K, Dellborg, M, Hultsberg-Olsson, G, Alstrom, P, Damm, TL, Erlinge, D, Brolin, G, Ravn-Fischer, PA, Johansson, P, Andreen, S, Linderfalk, C, Ram, B, Lindholm, CJ, Assarsson, E, Mooe, T, Lindberg, A, Paren, P, Moodh, J, Svensson, P, Andersson, I, Wodlin, P, Raschperger, A, Skogvard, P, Koch, A, Lind, N, Osberg, L, Nilsson, C, Svensson, K, Bengtsson, M, Samad, B, Nilsson, M, Berglund, E, Lundgren, C, Lindmark, K, Sundholm, C, Aladellie, L, Welin-Berger, B, Guneri, S, Dogan, NB, Ersanli, M, Coskun, U, Cayli, M, Seker, T, Camsari, A, Ozcan, T, Ongen, Z, Karadag, B, Boyaci, B, Sezenoz, B, Pekdemir, H, Hidayet, S, Erol, M, Yalcin, A, Sezer, M, Emet, S, Bozkurt, E, Ozen, MB, Lutay, Y, Dyadyk, O, Kholopov, L, Rudyk, I, Shaposhnikova, Y, Chopey, I, Ternuschak, T, Reshotko, D, Popova, G, Batushkin, V, Gema, A, Vizir, V, Berezyn, O, Lutai, M, Tovstukha, V, Shumakov, V, Pogurelska, O, Sirenko, Y, Rekovets, O, Kraiz, I, Kamenska, E, Tseluyko, V, Yakovleva, L, Yena, L, Artemenko, V, Koval, O, Kaplan, P, Karpenko, O, Nevolina, I, Bazilevych, A, Harbar, M, Rudenko, L, Beregova, O, Mostovyi, Y, Rasputina, L, Vatutin, M, Shevelok, A, Kovalenko, V, Polenova, N, Amosova, K, Tkachenko, L, Volkov, V, Zaprovalna, O, Storey, R, Thomas, M, Pell, A, Moriarty, A, Kinnin, M, Ahsan, A, Burton, J, ORourke, B, Young, J, Lang, C, Forbes, J, Rowlands, D, Hamill, S, Sprigings, D, Cadd, A, de Belder, M, Atkinson, B, Ramsey, M, Fagan, JC, Pye, M, Wright, L, Keeling, P, Hughes, D, Fraser, D, Phillips, H, Muthusamy, R, Lawan, M, Levy, T, Kennard, S, Bodalia, B, Mottram, J, Calvert, J, Brodie, K, Gunstone, A, Douglas, C, Trouton, T, Hunter, B, Gerber, R, Pepper, H, Mathur, A, Andiapen, M, Baumbach, A, Bowles, R, Hildick-Smith, D, McGregor, A, Loh, I, Plocky, J, Adams, K, Clemmer, K, Aggarwal, K, Burkhardt, V, Costa, M, Lemmertz, K, Anderson, J, York, T, Angiolillo, D, Green, E, Sperling, M, Vasquez, E, Aycock, G, Tatum, D, Amin, J, Davidson, A, Hendrix, E, Shepard, L, Strain, J, Michel, K, Talano, J, Szalanski, N, Berk, M, Ibarra, M, Bhagwat, R, Winterrowd, D, Bilazarian, S, Marsters, M, Blonder, R, Graf, L, Brilakis, E, Roesle, M, Byrd, L, Sullivan, A, Longo, J, Pennella, A, Westerhausen, D, Weil, R, Carr, K, Piazza, J, Carr, KW, Castello, R, Hawks, M, Chandna, H, Holly, D, Chandrashekhar, YS, Molinaro, N, Carter, M, Antonino, M, Kosmicki, D, Kelley, M, Richwine, R, Pazier, P, Glasgow, B, Bresee, S, Alexander, J, Concha, M, Martinez, E, Connelly, T, Schenks, R, Cooper, M, Garman, V, Condit, J, White, A, Fialkow, J, Mckercher, M, Luna, M, Soto, G, Prodafikas, J, Rambaud, B, Donovan, J, Mudd, D, Doty, W, Parsons, T, D'Urso, M, Bies, J, Han, J, Treadwell, M, Erickson, B, Dahl, P, Fattal, P, Braem, J, Felten, W, Prior, J, French, W, Barillas, O, Berger, R, Genova, E, Gelernt, M, Cockrell, D, Miller, G, Dumka, K, Gill, S, Elliot, S, Goldberg, R, Barrett, M, Gordon, P, Stern, L, Ayres, T, Rhule, V, Gupta, D, Holton, T, Haddad, T, Jain, J, Hakas, J, McSorley, J, Hamroff, G, Hollenweger, L, Wainwright, W, Jones, S, Casagrande, M, Casagrande, MG, Effat, M, Mardis, R, Henderson, D, Millard, D, Hermany, P, Meissner-Dengler, S, Hinchman, D, Luck, K, Hodson, R, Severson, L, Horwitz, P, Miller, K, Isserman, S, Moore, C, Jan, M, Bilyk, O, Kersh, R, DaCosta, A, Kim, E, Gonzales, C, Kmetzo, J, Taylor, D, Knutson, T, Belanger, B, Hage-Korban, E, Harrington, A, Murdock, D, Heiman, M, Dandekar, U, Khan, M, Khan, G, Lui, H, Holman, L, MacDonald, L, Derbyshire, S, Watkins, K, Mayer, N, Mitchell, B, McCullum, K, Delio-Cox, B, Mckay, R, Cloutier, J, McKenzie, M, Rodkey, K, McLaurin, B, Lack, A, Minisi, A, Jeter, D, Mitchell, R, Keane-Richmond, P, Stine, R, Bullivant, M, Morford, R, White, J, Oberoi, M, Geraldo-Abache, A, O'Dea, D, Mehta, R, Tang, N, Ong, S, Edwards, M, Osborne, J, Alonzo, C, Lev, V, Monroe, J, Popeil, L, Sorrentino, N, Portelli, J, Landi, T, Potu, R, Smith, N, Prashad, R, McDonough, C, Qureshi, M, Howe, A, Raikhel, M, Arsate, M, Rogers, W, Saag, L, Sangrigoli, R, Schwarz, L, Abu-Fadel, M, Hagee, A, Kinnaman, S, McDaniel, V, Wilson, V, Purcell, T, Roberts, J, Riofrio, K, Shah, U, Narang, S, Gredler, F, Knap, P, Shanes, J, Hansen, C, Sharma, M, Gibson, T, Sheldon, W, Bohn, A, Siegel, C, Tibbits, L, Singh, V, Nelson, M, Singh, N, Logwood, D, Randhawa, P, Vargas, B, Stegemoller, R, Cole, B, Aggarwal, R, Johnson, M, Steinhoff, J, Dunaway, B, Patel, K, Boomer, L, Taheri, H, Morgan, K, Tahirkheli, N, Santos, A, Thadani, U, Alexander, D, Bennett, W, Kelley, E, Thomas, J, Macnicholas, D, Varma, S, Evans, S, Vlastaris, A, Bittel, B, Voyce, S, Mack, B, Weiss, R, Fournier, T, Whitney, R, Orosco, C, Willis, J, VonGerichten, S, Wiseman, A, Sharrow, A, Wohns, D, Schuitema, J, Amin, M, Ramus, A, Wilson, W, Moeller, C, Newell, M, Tindell, L, Rivera, W, Kwierant, J, Bretton, E, Corbin, B, Labroo, A, Lopez, C, Brown, C, Craig, M, Lucca, M, Keinanen, T, Eisenberg, S, Fielding, M, Doorey, A, Squire, A, Suresh, D, Frost, J, Teklinski, A, Stone, B, Waksman, R, Griffin, S, Wharton, W, Blakely, J, Fishbein, G, Weller, C, Camp, A, Fisher, S, Meholick, A, Hejna, E, Anderson, R, Long, S, Parikh, S, Norton, N, Vijay, N, Washam, M, Smith, S, and Stepanov, N
- Abstract
BACKGROUND The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial infarction has not been established. We investigated the efficacy and safety of ticagrelor, a P2Y(12) receptor antagonist with established efficacy after an acute coronary syndrome, in this context. METHODS We randomly assigned, in a double-blind 1: 1: 1 fashion, 21,162 patients who had had a myocardial infarction 1 to 3 years earlier to ticagrelor at a dose of 90 mg twice daily, ticagrelor at a dose of 60 mg twice daily, or placebo. All the patients were to receive low-dose aspirin and were followed for a median of 33 months. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The primary safety end point was Thrombolysis in Myocardial Infarction (TIMI) major bleeding. RESULTS The two ticagrelor doses each reduced, as compared with placebo, the rate of the primary efficacy end point, with Kaplan-Meier rates at 3 years of 7.85% in the group that received 90 mg of ticagrelor twice daily, 7.77% in the group that received 60 mg of ticagrelor twice daily, and 9.04% in the placebo group (hazard ratio for 90 mg of ticagrelor vs. placebo, 0.85; 95% confidence interval [CI], 0.75 to 0.96; P = 0.008; hazard ratio for 60 mg of ticagrelor vs. placebo, 0.84; 95% CI, 0.74 to 0.95; P = 0.004). Rates of TIMI major bleeding were higher with ticagrelor (2.60% with 90 mg and 2.30% with 60 mg) than with placebo (1.06%) (P < 0.001 for each dose vs. placebo); the rates of intracranial hemorrhage or fatal bleeding in the three groups were 0.63%, 0.71%, and 0.60%, respectively. CONCLUSIONS In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding. (Funded by AstraZeneca; PEGASUS-TIMI 54 ClinicalTrials.gov number, NCT01225562.)
- Published
- 2015
141. Practical Difficulties Associated with the Indian Coal Washeries: A Case Study.
- Author
-
Mohanta, S., Sahoo, B., Sampaio, C. H., and Petter, C. O.
- Subjects
COAL washing ,COAL ,CLEAN coal technologies ,COAL sales & prices ,WATER storage ,COAL industry - Abstract
Beneficiation of lower grade coal continues to play a vital role for Indian coal industries, and it brings newer challenges to maintain its competitiveness in the global coal market. Studies have shown that the actual clean coal yield in most of the Indian coal washeries is much lower than that of the theoretical yield. Improper quantification of raw coal qualities and inappropriate maintenance of operating conditions for the processing equipments are often believed to be the two major causes for this lower yield. So, the importance of accurate quantification of these raw coal qualities has been demonstrated in this article. In addition, maximization of the plant yield has been illustrated through a case study. The results indicate that the yield could be increased up to 64.83%, which is nearly 21.64% higher than the plant's actual yield. This study has been carried out in two stages: Firstly, variation of available coal quality and the presence of near gravity material have been quantified, and secondly, maintenance of constant incremental quality approach has been verified. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
142. Health-related quality of life and pharmacotherapy in Parkinson's disease: results of a multi-country study of the EuroPA Study Group
- Author
-
Winter, Y, Reese, JP, Campenhausen, S von, Eggert, K, Balzer-Geldsetzer, M, Klotsche, J, Freire, R, Brozova, H, Longo, K, Peter, H, Gasser, J, Seppi, K, Popov, G, Mateus, C, Pfeiffer, KP, Skoupa, J, Boetzel, K, Gusev, E, Guekht, A, Ruzicka, E, Barone, P, Sampaio, C, Poewe, W, Oertel, WH, and Dodel, R
- Published
- 2024
- Full Text
- View/download PDF
143. Multifaceted nanominerals and ultrafine particles in phosphogypsum: a by-product of coal cleaning rejects
- Author
-
10059571 - Waanders, Frans Boudewijn, De Leão, Felipe B., Waanders, F., Taffarel, S., Sampaio, C., Lima, B., 10059571 - Waanders, Frans Boudewijn, De Leão, Felipe B., Waanders, F., Taffarel, S., Sampaio, C., and Lima, B.
- Published
- 2016
144. 712 - TERT promoter and FGFR3 mutations – a highly sensitive and non-invasive tool for bladder cancer recurrence detection
- Author
-
Leão, R., Batista, R., Sampaio, C., Peralta, P., Conceição, P., Sismeiro, A., Torres, N., Almeida, F., Prazeres, H., Vinagre, J., and Soares, P.
- Published
- 2019
- Full Text
- View/download PDF
145. GIGYF2 mutations are not a frequent cause of familial Parkinson's disease
- Author
-
Di Fonzo A., Fabrizio E., Thomas A., Fincati E., Marconi R., Tinazzi M., Breedveld G. J., Simons E. J., Chien H. F., Ferreira J. J., Horstink M. W., Abbruzzese G., Borroni B., Cossu G., Dalla Libera A., Fabbrini G., Guidi M., De Mari M., Lopiano L., Martignoni E., Marini P., Onofrj M., Padovani A., Stocchi F., Toni V., Sampaio C., Barbosa E. R., Meco G., Italian Parkinson Genetics Network, Oostra B. A, Bonifati V., MONTAGNA, PASQUALE, Erasmus MC other, Clinical Genetics, Di Fonzo A., Fabrizio E., Thomas A., Fincati E., Marconi R., Tinazzi M., Breedveld G.J., Simons E.J., Chien H.F., Ferreira J.J., Horstink M.W., Abbruzzese G., Borroni B., Cossu G., Dalla Libera A., Fabbrini G., Guidi M., De Mari M., Lopiano L., Martignoni E., Marini P., Onofrj M., Padovani A., Stocchi F., Toni V., Sampaio C., Barbosa E.R., Meco G., Italian Parkinson Genetics Network, Montagna P., Oostra B.A, and Bonifati V.
- Subjects
Proband ,Adult ,Parkinson's disease ,PARK11 ,Locus (genetics) ,Disease ,Biology ,Genetics ,GIGYF2 ,Mutation ,medicine ,Coding region ,Humans ,parkinson disease ,Gene ,Aged ,Parkinson Disease ,Middle Aged ,medicine.disease ,Pedigree ,Neurology ,Carrier protein ,Neurology (clinical) ,Geriatrics and Gerontology ,Carrier Proteins ,genetics ,gigyf2 ,mutation ,park11 ,parkinson's disease - Abstract
Mutations in the Grb10-interacting GYF protein 2 (GIGYF2) gene, within the PARK11 locus, have been nominated as a cause of Parkinson's disease in Italian and French populations. By sequencing the whole GIGYF2 coding region in forty-six probands (thirty-seven Italians) with familial Parkinson's disease compatible with an autosomal dominant inheritance, we identified no mutations. Our data add to a growing body of evidence suggesting that GIGYF2 mutations are not a frequent cause of PD. (C) 2009 Elsevier Ltd. All rights reserved.
- Published
- 2009
146. Mutant COQ2 in multiple-system atrophy
- Author
-
Sharma, M, Wenning, G, Krüger, R, European Multiple-System Atrophy Study Group (Sharma, M, Lichtner, P, Albanese, Donatella, Barone, P, Berciano, J, Bloem, Br, Coelho, M, Goldwurm, S, Infante, J, Klockgether, T, Ortega-Cubero, S, Del Sorbo, F, Pezzoli, G, Canesi, M, Tesei, S, Zecchinelli, A, Sacilotto, G, Meucci, N, Mariani, C, Cilia, R, Zini, M, Siri, C, Pellecchia, Mt, Picillo, M, Amboni, M, Schulte, C, Martí, Mj, Sampaio, C, Ferreira, J, Levin, J, Nilsson, Cf, Widner, H, Østergaard, K, Oertel, W, Pastor, P, Storch, A, Seppi, K, Geser, F, Krismer, F, Mahlknecht, P, Sprenger, Fs, Schöls, L, Tolosa, E, Wüllner, U, van de Warrenburg BP, Poewe, W, Gasser, T, and Krüger, R. ).
- Subjects
Genetics ,Male ,Alkyl and Aryl Transferases ,Parkinsonism ,Copy number analysis ,Locus (genetics) ,General Medicine ,Odds ratio ,Multiple System Atrophy ,Biology ,genetics [Alkyl and Aryl Transferases] ,medicine.disease ,3. Good health ,Exon ,Atrophy ,Start codon ,medicine ,Humans ,Female ,ddc:610 ,genetics [Multiple System Atrophy] ,Gene - Abstract
To the Editor: Tsuji and colleagues (July 18 issue)1 report that variants in the gene encoding coenzyme Q2 (COQ2) increase the risk of multiple-system atrophy. They observed homozygous COQ2 variants encoding the substitutions M78V and V343A in a consanguineous Japanese family with multiple-system atrophy subtype P and noted an association between V343A and sporadic multiple-system atrophy (minor-allele frequency [MAF], 4.8% of cases vs. 1.6% of controls; odds ratio, 3.05; 95% confidence interval, 1.65 to 5.85). However, the authors erroneously labeled human COQ2 variability from the fourth ATG start codon in exon 1, which encodes the smallest protein isoform and does not functionally complement the yeast coq2-null mutant.2 On the basis of the National Center for Biotechnology Information (NCBI) Reference Sequence (NM_015697.7), M78V should be labeled COQ2 c.382A→G (p.M128V) and V343A should be labeled c.1178T→C (p.V393A). We sequenced COQ2 in 299 Korean persons with multiple-system atrophy and 365 unaffected Korean persons and observed heterozygous COQ2 c.320G→C (encoding p.S107T) and c.382A→T (encoding p.M128R) in 2 patients with sporadic multiple-system atrophy; COQ2 c.1178T→C (p.V393A) was not associated with multiple-system atrophy (MAF, 2.7% of cases vs. 2.6% of controls). It is a challenge to reconcile recessive linkage of homozygous COQ2 mutations in familial multiple-system atrophy with a heterozygous, presumably dominant-negative association in sporadic multiple-system atrophy. Respectfully, we suggest that Tsuji and colleagues reconsider whether variations in COQ2 represent a risk factor for multiple-system atrophy. Genomic multiplications of the SNCA 6.4-Mb locus telomeric to COQ2 have previously been implicated in parkinsonism and multiple-system atrophy3; copy number analysis of linked loci, or genomewide analysis, should be considered.
- Published
- 2014
147. Entrepreneurial capacities as antecedents of business performance in Brazilian firms
- Author
-
Perin, M., Sampaio, C. H., Cegarra, J., and Lengler, J.
- Subjects
Entrepreneurial capacities ,Learning orientation ,Radical innovation ,Entrepreneurial orientation ,Organizational performance - Abstract
WOS:000337514100004 (Nº de Acesso Web of Science) We investigate the relationship between entrepreneurial capacities and firm performance. More specifically, we investigate the effects of radical innovation and learning orientation on business performance. We test the effects of entrepreneurial orientation on learning orientation and radical innovation. The results suggest that radical product innovation and companies' orientation to learn have a positive effect on organizational performance. Additionally, we find that entrepreneurial orientation positively influences a firm's capability to learn and innovate. Our findings also show a direct effect of learning orientation on radical innovation, which means that companies with a higher proclivity to learn are more likely to create products and processes, representing a major departure from the state of current knowledge
- Published
- 2014
148. Red flags for multiple system atrophy
- Author
-
Köllensperger M, Geser F, Seppi K, Stampfer Kountchev M, Sawires M, Scherfler C, Boesch S, Mueller J, Koukouni V, Quinn N, Pellecchia MT, Schimke N, Dodel R, Oertel W, Dupont E, Østergaard K, Daniels C, Deuschl G, Gurevich T, Giladi N, Coelho M, Sampaio C, Nilsson C, Widner H, Sorbo FD, Albanese A, Cardozo A, Tolosa E, Abele M, Klockgether T, Kamm C, Gasser T, Djaldetti R, Colosimo C, Meco G, Schrag A, Poewe W, Wenning GK, European MSA Study G.r.o.u.p., BARONE, PAOLO, Köllensperger, M, Geser, F, Seppi, K, Stampfer Kountchev, M, Sawires, M, Scherfler, C, Boesch, S, Mueller, J, Koukouni, V, Quinn, N, Pellecchia, Mt, Barone, Paolo, Schimke, N, Dodel, R, Oertel, W, Dupont, E, Østergaard, K, Daniels, C, Deuschl, G, Gurevich, T, Giladi, N, Coelho, M, Sampaio, C, Nilsson, C, Widner, H, Sorbo, Fd, Albanese, A, Cardozo, A, Tolosa, E, Abele, M, Klockgether, T, Kamm, C, Gasser, T, Djaldetti, R, Colosimo, C, Meco, G, Schrag, A, Poewe, W, Wenning, Gk, and European MSA Study, G. r. o. u. p.
- Published
- 2008
149. Diabetic foot with acute infection: treatment in the Portuguese Emergency Department
- Author
-
Neves,J., Matias,R., Formiga,A., Cabete,J., Moniz,L., Figueiredo,J., and Sampaio,C.
- Subjects
Úlcera do Pé Diabético ,úlcera pé diabético ,Tratamento ,Portugal ,pé isquémico ,pé neuropático ,isquemic foot ,pé diabético ,HSAC DER ,HSAC CIR ,infecção aguda de úlcera ,diabetic foot ulcer ,neuropathic foot ,diabetic foot ,Infecções ,acute infection ulcer - Abstract
O pé diabético é uma complicação major comum da Diabetes mellitus sendo o cirurgião geral o responsável pelo seu diagnóstico e tratamento. A infecção aguda é uma urgência médico-cirúrgica. Este artigo tem como objectivos orientar o cirurgião no diagnóstico e tratamento do pé diabético infectado no serviço de urgência. Antibioterapia de largo espectro, drenagem/ desbridamento cirúrgico no serviço de urgência, internamento, repouso do membro e apósitos adequados são medidas essenciais para o correcto tratamento do pé diabético com infecção moderada-grave. Os desbridamentos devem, sempre que possível, preservar a estrutura e funcionalidade do pé. A intervenção atempada é essencial para reduzir o número de amputações major, a mortalidade e custo social associados. Diabetic foot is a common major complication of Diabetes mellitus. The general surgeon is responsible for its diagnosis and treatment. Acute infection is a medical and surgical emergency. This article aims to guide the surgeon in the diagnosis and treatment of infected diabetic foot in the emergency department. Broad-spectrum antibiotics, surgical drainage/debridement in the emergency department, inpatient, lying of the member and appropriate dressings are essential for the proper treatment of the diabetic foot with moderate-severe infection. The debridement should preserve the structure and function of the foot. Early intervention is essential in order to reduce the number of major amputations and mortality and social cost associated.
- Published
- 2013
150. Depression rating scales in Parkinson's disease: critique and recommendations
- Author
-
Schrag A, Brown RG, Leentjens AF, McDonald WM, Starkstein S, Weintraub D, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz C.G., BARONE, PAOLO, Schrag, A, Barone, Paolo, Brown, Rg, Leentjens, Af, Mcdonald, Wm, Starkstein, S, Weintraub, D, Poewe, W, Rascol, O, Sampaio, C, Stebbins, Gt, and Goetz, C. G.
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.